The accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living systematic review and meta-analysis.

Lukas E. Brümmer[1]*, Stephan Katzenschlager[2]*, Mary Gaeddert[1], Christian Erdmann[3], Stephani Schmitz[1], Marc Bota[4], Maurizio Grilli[5], Jan Larmann[2], Markus A. Weigand[2], Nira R. Pollock[6], Aurélien Macé[7], Sergio Carmona[7], Stefano Ongarello[7], Jilian A. Sacks[7], Claudia M. Denkinger[1, 8]

* These authors contributed equally

1) Division of Tropical Medicine, Center for Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany
2) Department of Anesthesiology, Heidelberg University Hospital, Heidelberg, Germany
3) FH Muenster University of Applied Sciences, Muenster, Germany
4) Agaplesion Bethesda Hospital, Hamburg, Germany
5) Library, University Medical Center Mannheim, Mannheim, Germany
6) Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA USA
7) FIND, Geneva, Switzerland
8) German Center for Infection Research (DZIF), partner site Heidelberg University Hospital, Heidelberg, Germany

Keywords: SARS-CoV-2; Antigen Test; PCR; meta-analysis;

Running Title: Meta-Analysis: Rapid antigen tests for SARS-CoV-2

Corresponding author:
Claudia M. Denkinger
Division of Tropical Medicine, Center for Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany
Claudia.Denkinger@uni-heidelberg.de
+49 6221 56 36637

ABSTRACT

Background: SARS-CoV-2 antigen rapid diagnostic tests (Ag-RDTs) are increasingly being integrated in testing strategies around the world. Studies of the Ag-RDTs have shown variable performance. In this systematic review and meta-analysis, we assessed the clinical accuracy (sensitivity and specificity) of commercially available Ag-RDTs.

Methods and Results: We registered the review on PROSPERO (Registration number: CRD42020225140). We systematically searched multiple databases (PubMed, Web of Science Core Collection, medRvix and bioRvix, FIND) for publications evaluating the accuracy of Ag-RDTs for SARS-CoV-2 up until April 30th, 2021. Descriptive analyses of all studies were performed and when more than four studies were available, a random-effects meta-analysis was used to estimate pooled sensitivity and specificity in comparison to reverse transcriptase polymerase chain reaction testing. We assessed heterogeneity by subgroup analyses, and rated study quality and risk of bias using the QUADAS 2 assessment tool. From a total of 14,254 articles, we included 133 analytical and clinical studies resulting in 214 clinical accuracy data sets with 112,323 samples. Across all meta-analyzed samples, the pooled Ag-RDT sensitivity was 71.2% (95% confidence interval [CI] 68.2 to 74.0) and increased to 76.3% (CI 73.1 to 79.2) if analysis was restricted to studies that followed the Ag-RDT manufacturers' instructions. The LumiraDx showed the highest sensitivity with 88.2% (CI 59.0 to 97.5). Of instrument-free Ag-RDTs, Standard Q nasal performed best with 80.2% sensitivity (CI 70.3 to 87.4). Across all Ag-RDTs sensitivity was markedly better on samples with lower Ct-values, i.e., <20 (96.5%, CI 92.6 to 98.4) and <25 (95.8%, CI 92.3 to 97.8), in comparison to those with Ct ≥25 (50.7%, CI 35.6 to 65.8) and ≥30 (20.9%, CI 12.5 to 32.8). Testing in the first week from symptom onset resulted in substantially higher sensitivity (83.8%, CI 76.3 to 89.2) compared to testing after one week (61.5%, CI 52.2 to 70.0). The best Ag-RDT sensitivity was found with anterior nasal sampling (75.5%, CI 70.4 to 79.9) in comparison to other sample types (e.g., nasopharyngeal 71.6%, CI 68.1 to 74.9) although CIs were overlapping. Concerns of bias were raised across all data sets, and financial support from the manufacturer was reported in 24.1% of data sets. Our analysis was limited by the included studies' heterogeneity in design and reporting, making it difficult to draw conclusions from.

Conclusion: In this study we found that Ag-RDTs detect the vast majority of cases within the first week of symptom onset and those with high viral load. Thus, they can have high utility for diagnostic purposes in the early phase of disease, making them a valuable tool to fight the spread of SARS-CoV-2. Standardization in conduct and reporting of clinical accuracy studies would improve comparability and use of data.

AUTHOR SUMMARY

Why was this study done?

- Antigen rapid diagnostic tests (Ag-RDTs) are considered an important diagnostic tool to fight the spread of SARS-CoV-2
- An increasing number of Ag-RDTs is offered on the market, and a constantly growing body of literature evaluating their performance is available
- To inform decision makers about the best test to choose, an up to date summary of their performance is needed

What did the researchers do and find?

- On a weekly basis, we search multiple data bases for evaluations of Ag-RDTs detecting SARS-CoV-2 and post the results on www.diagnosticsglobalhealth.org
- Based on the search results up until April 30th, 2021, we conducted a systematic review and meta-analysis, including a total of 133 clinical and analytical accuracy studies
- Across all meta-analyzed studies, when Ag-RDTs were performed according to manufacturers' recommendations, they showed a sensitivity of 76.3% (CI 73.1 to 79.2), with the LumiraDx (sensitivity 88.2%, CI 59.0 to 97.5) and of the instrument-free Ag-RDT Standard Q (74.9% sensitivity, CI 69.3 to 79.7) performing best.
- Across all Ag-RDTs, sensitivity increased to 95.8% (CI 92.3 to 97.8) when restricting the analysis to samples with high viral loads (i.e., a Ct-value <25) and to 83.8% (CI 76.3 to 89.2) when tests were performed on patients within the first week after symptom onset

What do these findings mean?

- Ag-RDTs detect the vast majority of cases within the first week of symptom onset and those with high viral load. Thus, they can have high utility for diagnostic purposes in the early phase of disease
- Out of all assessed tests, the Lumira Dx showed the highest accuracy. The Standard Q was the best performing test when only considering those that don't require an instrument
- A standardization of reporting methods for clinical accuracy studies would enhance future test-comparisons

97 **ABBREVIATIONS**

98 Ag-RDT = antigen rapid diagnostic test

99 AN/MT = anterior nasal or mid-turbinate

100 BAL/TW = bronchoalveolar lavage or throat wash

101 CI = confidence interval

102 Ct-value = cycle threshold value

103 FIND = Foundation for Innovative New Diagnostics

104 FP = false positive

105 FN = false negative

106 IFU = instructions for use

107 LRT = lower respiratory tract

108 ML = milliliter

109 N = sample size

110 NP = nasopharyngeal

111 OP = oropharyngeal

112 PFU = plaque forming units

113 RT-PCR = reverse transcriptase polymerase chain reaction

114 TP = true positive

115 TN = true negative

116 VTM/UTM = viral or universal transport medium

INTRODUCTION

As the COVID-19 pandemic continues around the globe, antigen rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2 are seen as an important diagnostic tool to fight the virus' spread [1,2]. The number of Ag-RDTs on the market is increasing constantly [3]. Initial data from independent evaluations suggests that the performance of SARS-CoV-2 Ag-RDTs may be lower than what is reported by the manufacturers. In addition, Ag-RDT accuracy seems to vary substantially between tests [4-6].

With the increased availability of Ag-RDTs, an increasing number of independent validations have been published. Such evaluations differ widely in their quality, methods and results, making it difficult to assess the true performance of the respective tests [7]. To inform decision makers on the best choice of individual tests, an aggregated, widely available and frequently updated assessment of the quality, performance and independence of the data is urgently necessary. While other systematic reviews have been published, they only include data up until Nov 2020 [8-11], exclude preprints [12], or were industry sponsored [13]. In addition, only one assessed the quality of studies in detail, with data up until Nov, 2020 [7,11].

With our systematic review and meta-analysis, we aim to close this gap in the literature and link to a website (www.diagnosticsglobalhealth.org) that is regularly updated.

133 **METHODS**

134 We developed a study protocol following standard guidelines for systematic reviews [14,15],
135 which is available in the Supplement (S15). We have also completed the PRISMA checklist, which can
136 be found in the Supplement (S1_PRISMA_Checklists) as well. Furthermore, we registered the review
137 on PROSPERO (Registration number: CRD42020225140).

138

139 SEARCH STRATEGY

140 We performed a search of the databases PubMed, Web of Science, medRxiv and bioRxiv using
141 search terms that were developed with an experienced medical librarian (MauG) using combinations
142 of subject headings (when applicable) and text-words for the concepts of the search question. The
143 main search terms were "Severe Acute Respiratory Syndrome Corona-virus 2", "COVID-19",
144 "Betacoronavirus", "Coronavirus" and "Point of Care Testing". The full list of search terms is available
145 in the Supplement (S2). We also searched the FIND website (https://www.finddx.org/sarscov2-eval-
146 antigen/) for relevant studies manually. We performed the search up until April 30th, 2021. No lan-
147 guage restrictions were applied.

148

149 INCLUSION CRITERIA

150 We included studies evaluating the accuracy of commercially available Ag-RDTs to establish a
151 diagnosis of a SARS-CoV-2 infection against reverse transcriptase polymerase chain reaction (RT-PCR)
152 or cell culture as reference standard. We included all study populations irrespective of age, presence
153 of symptoms, or the study location. We considered cohort studies, nested cohort studies, case-
154 control or cross-sectional studies and randomized studies. We included both peer reviewed publica-
155 tions and preprints.

156 We excluded studies in which patients were tested for the purpose of monitoring or ending
157 quarantine. Also, publications with a population size smaller than 10 were excluded. Although the

158 size threshold of 10 is arbitrary, such small studies are more likely to give unreliable estimates of
159 sensitivity or specificity.
160
161 INDEX TESTS
162 Ag-RDTs for SARS-CoV-2 aim to detect infection by recognizing viral proteins. Most Ag-RDTs use
163 specific labeled antibodies attached to a nitrocellulose matrix strip, to capture the virus antigen. Suc-
164 cessful binding of the antibodies to the antigen is either detected visually (through the appearance of
165 a line on the matrix strip (lateral flow assay)) or requires a specific reader for fluorescence detection.
166 Microfluidic enzyme-linked immunosorbent assays have also been developed. Ag-RDTs typically pro-
167 vide results within 10 to 30 minutes [6].
168
169 REFERENCE STANDARD
170 Viral culture detects viable virus that is relevant for transmission but is available in research set-
171 tings only. Since RT-PCR tests are more widely available and SARS-CoV-2 RNA (as reflected by RT-PCR
172 cycle threshold (Ct) value) highly correlates with SARS-CoV-2 antigen quantities, we considered it an
173 acceptable reference standard for the purposes of this systematic review [16]. It is of note that there
174 is currently no international standard for the classification of viral load available.
175
176 STUDY SELECTION AND DATA EXTRACTION
177 Two reviewers (LEB and CE, LEB and SS or LEB and MB) reviewed the titles and abstracts of all
178 publications identified by the search algorithm independently, followed by a full-text review for
179 those eligible, to select the articles for inclusion in the systematic review. Any disputes were solved
180 by discussion or by a third reviewer (CMD).
181 A full list of the parameters extracted is included in the Supplement (S14) and the data extrac-
182 tion file is available upon request. Studies that assessed multiple Ag-RDTs or presented results based
183 on differing parameters (e.g., various sample types) were considered as individual data sets.

184 At first, four authors (SK, CE, SS, MB) extracted five randomly selected papers in parallel to align
185 data extraction methods. Afterwards, data extraction and the assessment of methodological quality
186 and independence from test manufacturers (see below) were performed by one author per paper
187 (SK, CE, SS, MB) and controlled by a second (LEB, SK, SS, MB). Any differences were resolved by dis-
188 cussion or by consulting a third author (CMD).
189
190 STUDY TYPES
191 We differentiated between clinical accuracy studies (performed on clinical samples) or analytical
192 accuracy studies (performed on spiked samples with a known quantity of virus). Analytical accuracy
193 studies can differ widely in methodology, impeding an aggregation of their results. Thus, while we
194 extracted the data for both kinds of studies, we only considered data from clinical accuracy studies as
195 eligible for the meta-analysis. Separately, we summarized the results of analytical studies and com-
196 pared them with the results of the meta-analysis for individual tests.
197
198 ASSESSMENT OF METHODOLOGICAL QUALITY
199 The quality of the clinical accuracy studies was assessed by applying the QUADAS-2 tool [17].
200 The tool evaluates four domains: patient selection, index test, reference standard, and flow and tim-
201 ing. For each domain, the risk of bias is analyzed using different signaling questions. Beyond the risk
202 of bias, the tool also evaluates the applicability of the study of each included study to the research
203 question for every domain. The QUADAS 2 tool was adjusted to the needs of this review and can be
204 found in the Supplement (S3).
205
206 ASSESSMENT OF INDEPENDENCY FROM MANUFACTURERS
207 We examined whether a study received financial support from a test manufacturer (including
208 the free provision of Ag-RDTs), whether any study author was affiliated with a test manufacturer, or
209 a respective conflict of interest was declared. Studies were judged not to be independent from the

210 test manufacturers if at least one of these aspects was present, otherwise they were considered to
211 be independent.
212
213 STATISTICAL ANALYSIS AND DATA SYNTHESIS
214 We extracted raw data from the studies and recalculated performance estimates where possi-
215 ble based on the extracted data. The raw data can be found in the Supplement (S4). We prepared
216 forest plots for the sensitivity and specificity of each test and visually evaluated the heterogeneity
217 between studies. If four or more data sets were available with at least 20 positive RT-PCR samples
218 per data set for a predefined analysis, a meta-analysis was performed. We report point estimates of
219 sensitivity and specificity for SARS-CoV-2 detection compared to the reference standard along with
220 95% confidence intervals (CI) using a bivariate model (implemented with the 'reitsma' command
221 from the R package "mada" version 0.5.10). When there were less than four studies for an index test,
222 only a descriptive analysis was performed and accuracy ranges were reported. In sub-group analyses
223 where papers presented data only on sensitivity, a univariate random-effects inverse variance meta-
224 analysis was done (using the 'metagen' command from the R package "meta" version 4.11-0). We
225 predefined the following subgroups for meta-analysis: by Ct-value range, by sampling and testing
226 procedure in accordance with manufacturer's instructions as detailed in the instructions for use
227 (henceforth called IFU-conforming) vs. not IFU-conforming, age (<18; ≥18), sample type, by presence
228 or absence of symptoms, symptom duration (<7 days vs. ≥7 days), by viral load and by type of RT-PCR
229 used.
230 In an effort to use as much of the heterogeneous data as possible, the cut-offs for the Ct-value
231 groups were relaxed by 2-3 points within each range. The <20 group included values reported up to
232 ≤20, the <25 group included values reported as ≤24 or <25 or 20-25, the <30 group included values
233 from ≤29 to ≤33 and 25-30. The ≥25 group included values reported as ≥25 or 25-30, the ≥30 group
234 included values from ≥30 to ≥35. For categorization by sample type, we assessed (1) nasopharyngeal
235 (NP) alone or combined with other (e.g., oropharyngeal (OP)), (2) OP alone, (3) anterior nasal or mid-

236 turbinate (AN/MT), (4) a combination of bronchial alveolar lavage and throat wash (BAL/TW) or (5)
237 saliva. For categorization by age, the pediatric group included values reported as <16 or <18, whereas
238 values reported as ≥16 or ≥18 were included in the adult group. Analyses were preformed using R
239 4.0.3 (R Foundation for Statistical Computing, Vienna, Austria).

240 We aimed to do meta-regression to examine the impact of covariates including symptom dura-
241 tion and Ct-value range. We also performed the Deeks' test for funnel-plot asymmetry as recom-
242 mended to investigate publication bias for diagnostic test accuracy meta-analyses ([18], using the
243 'midas' command in Stata version 15); a p-value<0.10 for the slope coefficient indicates significant
244 asymmetry.

245

246 SENSITIVITY ANALYSIS

247 Two types of sensitivity analyses were planned: an estimation of sensitivity and specificity ex-
248 cluding case-control studies, and estimation of sensitivity and specificity excluding non-peer-
249 reviewed studies. We compared the results of each sensitivity analysis against overall results to as-
250 sess the potential bias introduced by considering case-control studies and non-peer reviewed stud-
251 ies.

RESULTS

SUMMARY OF STUDIES

The systematic search resulted in 14,254 articles. After removing duplicates, 8,921 articles were screened, and 266 papers were considered eligible for full-text review. Of these, 148 were excluded because they did not present primary data [13,19-131] or the Ag-RDT was not commercially available [16,132-164], leaving 133 studies to be included in the systematic review (Fig 1) [4,165-296].

At the end of the data extraction process, 37 studies were still in preprint form [4,171,173,174,177,180,190,192,201,204,205,207,211,214-216,218,220,222,223,225,227,231,233,234,238,240,244,247,253,257,265,267,284,287,290,293]. All studies were written in English, except for two in Spanish [175,280]. Out of the 133 studies, nine reported analytical accuracy [173,191,198,208,227,256,274,275,282] and the remaining 124 reported clinical accuracy.

The clinical accuracy studies were divided into 214 data sets, while the nine analytical accuracy studies accounted for 62 data sets. A total of 61 different Ag-RDTs were evaluated (48 lateral flow with visual readout, twelve requiring an automated reader), with 56 being assessed in a clinical accuracy study. 39 studies reported data for more than one test and 19 studies of these conducted a head-to-head assessment, i.e., testing at least two Ag-RDTs on the same sample or participant. The reference method was RT-PCR in all except one study, which used viral culture [281].

The most common reasons for testing were the occurrence of symptoms (55/19.9% of data sets), screening independent of symptoms (19/6.9%) and close contact to a SARS-CoV-2 confirmed case (10/3.6%). In 79 (28.6%) of the data sets, persons were tested due to more than one of the reasons mentioned before and for 163 (59.1%) the reason for testing was unclear.

In total, 113,242 Ag-RDTs were performed, 112,323 (99.2%) in clinical accuracy studies and 919 (0.8%) in analytical accuracy studies. In the clinical accuracy studies, the mean number of samples per study was 525 (Range 16 to 6,954). Only 4,752 (4.2%) tests were performed on pediatric samples and 21,351 (18.9%) on samples from adults. For the remaining 87,139 (76.9%) samples it was not

278 specified whether they originate from adults or children. Symptomatic patients comprised 36,981
279 (32.7%) samples, 32,799 (29.0%) samples originated from asymptomatic patients, and for 42,462
280 (38.4%) samples the patient's symptom status could not be identified. The most common sample
281 type evaluated was NP and mixed NP/OP (67,036 samples, 59.2%), followed by AN/MT (27,045 sam-
282 ples, 23.9%). There was substantially less testing done for the other sample types, with 6,254 (5.5%)
283 tests done from OP samples, 1,351 (1.2%) from saliva, 219 (0.2%) from BAL/TW and for 11,337
284 (10.0%) tests we could not tell the type of sample.

285 Of the data sets assessing clinical accuracy, 89 (41.6%) performed testing according to the man-
286 ufacturers' recommendations (i.e., IFU-conforming), while 100 (46.7%) were not IFU-conforming and
287 for 25 (11.7%) it was unclear. The most common deviations from the IFU were (1) use of samples
288 that were prediluted in transport media not recommended by the manufacturer (80 data sets; seven
289 unclear), (2) use of banked samples (60 data sets; 14 unclear) and (3) a sample type that was not
290 recommended for Ag-RDTs (17 data sets; 8 unclear).

291 A summary of the tests evaluated in clinical accuracy studies, including study author, sample
292 size, sample type, sample condition and IFU conformity, can be found in Table 1. The Panbio test by
293 Abbott Rapid Diagnostics (Germany; henceforth called Panbio) was reported the most frequently
294 with 39 (18.2%) data sets and 28,089 (25.0%) tests, while Standard Q test by SD Biosensor (South
295 Korea; distributed in Europe by Roche, Germany; henceforth called Standard Q) was assessed in 37
296 (17.3%) data sets with 16,820 (15.0%) tests performed. Detailed results for each clinical accuracy
297 study are available in the Supplement (S 4).

298

299 METHOLOGICAL QUALITY OF STUDIES

300 The findings on study quality using the QUADAS 2 tool are presented in Fig 2. In 190 (88.8%) da-
301 ta sets a relevant patient population was assessed. However, for only 44 (20.6%) of the data sets the
302 patient selection was considered representative of the setting and population chosen (i.e., they

303 avoided inappropriate exclusions, a case-control design and enrollment occurred consecutive or ran-
304 domly).

305 The conduct and interpretation of the index tests was considered to have low risk for introduc-
306 tion of bias in 113 (52.8%) of data sets (through e.g., appropriate blinding of persons interpreting the
307 visual read-out). However, for 99 (46.3%) of data sets sufficient information to clearly judge the risk
308 of bias was not provided. In only 89 (41.6%) of data sets the Ag-RDTs were performed according to
309 IFU, while 100 (46.7%) were not IFU-conforming, potentially impacting the diagnostic accuracy (for
310 25 (11.7%) of data sets the IFU status was unclear).

311 In 81 (37.9%) of data sets the reference standard was performed before the Ag-RDT, or the op-
312 erator conducting the reference standard was blinded to the Ag-RDT results, resulting in a low risk of
313 bias. In almost all other data sets (132/61.7%) this risk could not be assessed due to missing data. The
314 applicability of the reference test was judged to be of low concern for all data sets, as cell culture or
315 RT-PCR are expected to adequately define the target condition.

316 In 209 (97.7%) data sets, the sample for the index test and reference test were obtained at the
317 same time, while this was unclear in five (2.3%). All samples included in a data set were applied to
318 the same type of RT-PCR in 145 (67.8%) data sets, while different types of RT-PCR were used within
319 the same data set in 50 (23.4%) data sets. For 19 (8.9%), it was unclear. Furthermore, for 11 (5.1%) of
320 data sets, there was a concern that not all selected patients were included in the analysis.

321 Finally, 32 (24.1%) of the studies received financial support from the Ag-RDT manufacturer and
322 in another nine (6.8%) employment of the authors by the manufacturer of the Ag-RDT studied was
323 indicated. Overall, a conflict of interest was found in 33 (24.8%) of the studies.

324

325 DETECTION OF SARS-COV-2 INFECTION

326 Out of 214 clinical data sets (from 124 studies), 20 were excluded from the meta-analysis, as
327 they included less than 20 RT-PCR positive samples. Further 21 data sets were missing either sensitiv-
328 ity or specificity and were only considered for univariate analyses. Across the remaining 173 data

329 sets, including any test and type of sample, the pooled sensitivity and specificity were 71.2% (95%CI
330 68.2 to 74.0) and 98.9% (95%CI 98.6 to 99.1), respectively. If testing was performed in conformity
331 with IFU, sensitivity increased to 76.3% (95%CI 73.1 to 79.2) compared to not IFU-conforming testing
332 with a sensitivity of 65.9% (95%CI 60.6 to 70.8). Pooled specificity was similar in both groups (99.1%
333 (95% CI 98.8-99.4)and 98.3% (95% CI 97.7 to 98.8), respectively).
334
335 ANALYSIS OF SPECIFIC TESTS
336 Based on 119 data sets with 71,424 tests performed, we were able to perform bivariate meta-
337 analysis of the sensitivity and specificity for twelve different Ag-RDTs (Fig 3A). Across these, pooled
338 estimates of sensitivity and specificity on all samples were 72.1% (95%CI 68.8 to 75.3) and 99.0%
339 (95% CI 98.7 to 99.2), which were very similar to the overall pooled estimate across all meta-analyzed
340 data sets (71.2% and 98.9%, above).
341 The highest pooled sensitivity was found for the SARS-CoV-2 Antigen Test by LumiraDx (United
342 Kingdom; henceforth called LumiraDx) and the Lumipulse G SARS-CoV-2 Ag by Fujirebio (Japan;
343 henceforth called Lumipulse G) with 88.2% (95% CI 59.0 to 97.5) and 87.2% (95% CI 78.0 to 92.9),
344 respectively. The Sofia SARS Antigen FIA by QUIDEL (California, US; henceforth called Sofia) had a
345 pooled sensitivity with 77.4% (95% CI 74.2 to 80.3). Of the non-instrument tests, the Standard Q and
346 the Standard Q nasal test by SD Biosensor (South Korea; distributed in Europe by Roche, Germany;
347 henceforth called Standard Q nasal) performed best with a pooled sensitivity of 74.9% (95% CI 69.3
348 to 79.7) and 80.2% (95% CI 70.3 to 87.4), respectively. The pooled sensitivity for Panbio was 71.8%
349 (95%CI 65.4 to 77.5). From all Ag-RDTs, the COVID-19 Ag Respi-Strip by Coris BioConcept (Belgium;
350 henceforth called Coris) had the lowest pooled sensitivity of 40.0% (95% CI 28.7 to 52.4).
351 The pooled specificity was above 98% for all of the tests, except for the Standard F by SD Bio-
352 sensor (South Korea) and Lumipulse G with specificities of 97.7% (95% CI 96.6 to 98.5) and 96.7%
353 (95% CI 88.6 to 99.1), respectively. Hierarchical summary receiver-operating characteristic for Stand-
354 ard Q and LumiraDx are available in the Supplement (S6).

355 Three Ag-RDTs did not have sufficient data to allow for a bivariate meta-analysis, wherefore a
356 univariate analysis was conducted (Fig 3B). For the INNOVA SARS-CoV-2 Antigen Rapid Qualitative
357 Test by Innova Medical Group (California, US) this resulted in a pooled sensitivity and specificity of
358 76.1% (95% CI 68.1 to 84.1) and 99.4% (95% CI 98.7 to 100), respectively. For the NADAL by NAL von
359 Minden (Germany) and the COVID-19 Rapid Antigen Visual Read by SureScreen (United Kingdom),
360 sufficient data was only available to analyze sensitivity, resulting in polled sensitivity estimates of
361 58.4% (95% CI 29.2 to 87.6) and 58.0% (95% CI 38.3 to 77.6) and, respectively.

362 The remaining 35 Ag-RDTs did not present sufficient data for neither a uni- nor a bivariate meta-
363 analysis. However, 9/35 have results presented in more than one data set and are summarized in
364 Table 2. Herein, the widest ranges of sensitivity were found for the ESPLINE SARS-CoV-2 by Fujirebio
365 (Japan) with sensitivity reported between 8.1% and 80.7%, and the RIDA®QUICK SARS-CoV-2 Antigen
366 by R-Biopharm (Germany) with sensitivity between 39.2% and 77.6%, both with three data sets each.
367 In contrast, two other test with two data sets each showed the least variability in sensitivity: the
368 Zhuhai Encode Medical Engineering, SARS-CoV-2 Antigen Rapid Test (China) reported sensitivity be-
369 tween 74.0% and 74.4% and the COVID-19 Rapid Antigen Flourescent by SureScreen (UK) reported
370 sensitivity between 60.3% and 69.0%. However, for both tests both data sets originated from the
371 same studies. Overall, the lowest sensitivity range was reported for the SARS-CoV-2 Antigen Rapid
372 Test by MEDsan (Germany) with 36.5% to 45.2% across two data sets. The specificity ranges were
373 above 96% for most of the tests. A notable outlier was the 2019-nCov Antigen Rapid Test Kit by
374 Shenzhen Bioeasy Biotechnology (China; henceforth called Bioeasy), reporting the worst with a speci-
375 ficity as low as 85.6% in one study. Forest plots for the data sets for each Ag-RDT are provided in the
376 Supplement (S5). The remaining 26 Ag-RDTs that were evaluated in one data set only are included in
377 Table 1 and Supplement (S5).

378 In total, 16 studies accounting for 53 data sets conducted head-to-head clinical accuracy evalua-
379 tions of different tests using the same sample(s) from the same participant. These data sets are un-
380 derlined in Table 1; 15 such studies included more than 100 samples, and one study included too few

381 samples to draw clear conclusions [286]. Four studies performed their head-to-head evaluation as
382 per manufacturers' instructions and on symptomatic patients. Across three of them, the Standard Q
383 (sensitivity 73.2% to 91.2%) and the Standard Q nasal (sensitivity 82.5% to 91.2%) showed a similar
384 range of sensitivity [207,215,271]. The fourth reported a sensitivity of 56.4% (95% CI 44.7 to 67.6) for
385 the Biocredit Covid-19 Antigen rapid test kit by RapiGEN (South Korea; henceforth called Rapigen)
386 and 52.6% (95% CI 40.9 to 64) for the SGTi-flex COVID-19 Ag by Sugentech (South Korea) [233].
387 All other head-to-head comparisons were not IFU-conforming. In one of these, the Rapid
388 COVID-19 Ag Test by Healgen (sensitivity 77.1%) performed better than the Standard Q and Panbio
389 (sensitivity 69.8% and 67.7%, respectively) [178]. In contrast to the overall findings of the meta-
390 analysis above, two other head-to-head studies found that both the Standard Q (sensitivity 43.6%
391 and 49.4) and Panbio (sensitivity 38.6% and 44.6%) had lower performance than the CLINITEST® Rap-
392 id COVID-19 Antigen Test by Siemens Healthineers (Germany; henceforth called Clinitest), which
393 reported sensitivities 51.5% and 54.9% [167,279]. However, another study found both the Standard
394 Q and Panbio (sensitivity 81.0% and 82.9%, respectively) to have a higher accuracy than the Sofia
395 (sensitivity 80.4%) [196].
396
397 SUBGROUP ANALYSIS
398 The results are presented in Fig 4. Detailed results for the subgroup analysis are available in the
399 Supplement (S7 to 11).
400
401 **Subgroup analysis by Ct-values**
402 High sensitivity was achieved for Ct-values <20 with 96.5% (95% CI 92.6 to 98.4). The pooled
403 sensitivity for Ct-values <25 was markedly better at 95.8% (95% CI 92.3 to 97.8) compared to the
404 group with Ct ≥ 25 at 50.7% (95% CI 35.6 to 65.8). A similar pattern was observed when the Ct-values
405 were analyzed using cut-offs <30 or ≥30, resulting in a sensitivity of 79.9% (95% CI 70.3 to 86.9) and
406 20.9% (95% CI 12.5 to 32.8), respectively (Fig 4A).

407 In addition, it was possible to meta-analyze test specific pooled sensitivity for the Panbio: 97.7%
408 sensitivity (95% CI 95.3 to 98.9) for Ct-value <20, 95.8% (95% CI 92.3 to 97.8) for Ct-value <25 and
409 83.4% (95% CI 69.1 to 91.9) for Ct-value <30. For Ct-value ≥25 sensitivity was 61.2% (95% CI 38.8 to
410 79.7) and 30.5% (95% CI 16.0 to 50.4) for Ct-value ≥30. For the other Ag-RDTs only limited data was
411 available, which is presented in the supplements (S10).
412
413 **Subgroup analysis by IFU conformity**
414 The summary results are presented in Fig 4B. When assessing only studies with an IFU-
415 conforming testing, pooled sensitivity from 81 datasets with 49,643 samples was 76.3% (95% CI 73.1
416 to 79.2). When not IFU-conforming sampling (75 data sets, 31,416 samples) was performed sensitivi-
417 ty decreased to 65.9% (95% CI 60.6 to 70.8).
418 For five tests it was possible to calculate pooled sensitivity estimates only including data sets
419 with an IFU-conforming testing: Panbio (sensitivity of 76.5% (95% CI 69.5 to 82.3); 17 data sets,
420 12,856 samples), Standard Q (sensitivity of 79.3% (95% CI 73.5 to 84.1); 15 data sets, 6,584 samples),
421 BinaxNOW (sensitivity of 61.8% (95% CI 48.0 to 74.0); 4 data sets, 8,163 samples), Rapigen (sensitivi-
422 ty of 67.1% (95% CI 50.4 to 80.4); 4 data sets, 1,934 samples) and Standard Q nasal (sensitivity of
423 83.8% (95% CI 77.8 to 88.4); 5 data sets, 683 samples). Specificity was above 98.6% for all tests.
424 In contrast, when the Panbio (14 data sets, 9,233 samples) and Standard Q (14 data sets, 4,714
425 samples) tests were not performed according to IFU, pooled sensitivity decreased to 64.3% (95% CI
426 50.9 to 75.8) and 67.4 (95% CI 57.2 to 76.2), respectively.
427
428 **Subgroup analysis by sample type**
429 Most data sets evaluated NP or combined NP/OP swabs (122 data sets and 59,810 samples) as
430 the sample type for the Ag-RDT. NP or combined NP/OP swabs achieved a pooled sensitivity of 71.6%
431 (95% CI 68.1 to 74.9). Data sets that used AN/MT swabs for Ag-RDTs (32 data sets and 25,814 sam-
432 ples) showed a summary estimate for sensitivity of 75.5% (95% CI 70.4 to 79.9). This was confirmed

433 by two studies that reported direct head-to-head comparison of NP and MT samples from the same
434 participants using the same Ag-RDT (Standard Q), where the two sample types showed equivalent
435 performance [271,272]. Analysis of performance with an OP swab (seven data sets, 5,165 samples),
436 showed pooled sensitivity of only 53.1% (95%CI 40.9 to 65.0). Saliva swabs (four data sets, 1,088
437 samples) showed the lowest pooled sensitivity with only 37.9% (95% CI 11.8 to 73.5) (Fig 4C).
438 We were not able to perform a subgroup meta-analysis for BAL/TW due to insufficient data as
439 there was only one study with 73 samples evaluating the Rapigen, Panbio and Standard Q [286].
440 However, BAL/TW would in any case be considered an off-label use.
441
442 **Subgroup analysis in symptomatic and asymptomatic patients**
443 Within the data sets possible to meta-analyze, 17,964 (54.1%) samples were from symptomatic
444 and 15,228 (45.9%) from asymptomatic patients. The pooled sensitivity for symptomatic patients was
445 markedly different compared to asymptomatic patients with 76.7% (95% CI 70.6 to 81.9) vs. 52.5%
446 (95% CI 43.7 to 61.1). Specificity was 99% for both groups (Figu 4D). Median Ct-values differed in
447 symptomatic and asymptomatic patients. For those studies where it was possible to extract a median
448 Ct-value, it ranged from 20.5 to 27.0 in symptomatic [170,207,226,258,271,272] and from 27.2 to
449 30.5 in asymptomatic [170,201,258] patients.
450
451 **Subgroup analysis comparing symptom duration**
452 Data were analyzed for 5,538 patients with symptoms less than 7 days, but very limited data
453 were available for patients with symptoms ≥ 7 days (397 patients). The pooled sensitivity for patients
454 with onset of symptoms <7 days was 83.8% (95% CI 76.3 to 89.2) which is markedly higher than the
455 61.5% (95% CI 52.2 to 70.0) sensitivity for individuals tested ≥ 7 days from onset of symptoms (Fig
456 4D).
457
458 **Subgroup analysis by age**

459 For adult patients, it was possible to pool estimates across 3,837 samples, whereas the pediatric
460 group included 7,326 samples. Sensitivity and specificity were 64.3% (95% CI 54.7 to 72.9) and 99.4%
461 (95% CI 98.9 to 99.7) in mostly symptomatic patients <18 years. In patients ≥18, sensitivity increased
462 to 74.8% (95% CI 66.5 to 81.6), while the specificity was similar (98.7%, 95% CI 97.2 to 99.4) (Fig 4E).
463

464 **Subgroup analysis by type of RT-PCR and viral load**

465 We were not able to perform a meta-analysis for the subgroups by type of RT-PCR or viral load
466 (viral copies/mL) due to insufficient data.

467 In 152 (71.0%) of the data sets only one type of RT-PCR was used, whereas 37 (17.3%) tested
468 samples in the same data set using different RT-PCRs. For 25 (11.7%) of the data sets the type of RT-
469 PCR was not reported. The Cobas® SARS-CoV-2 Test from Roche (Germany) was used most frequently
470 in 63 (29.4%) of the data sets, followed by the Allplex® 2019 n-CoV Assay from Seegene in 41 (19.2%)
471 and the SARS CoV-2 assay from TaqPath in 20 (9.3%) of the data sets

472 Median sensitivity in samples with viral load of >5 log 10 copies/ml was 72.4% (range 46.9 to
473 100), 97.8% (range 71.4 to 100) for >6 log 10 copies/ml and 100% (range 93.8 to 100) for >7 log 10
474 copies/ml, showing that the sensitivity increases with increasing viral load.
475

476 **Meta regression**

477 We were not able to perform a meta-regression due to the considerable heterogeneity in re-
478 porting sub-groups, which resulted in too few studies with sufficient data for comparison.
479

480 **Publication Bias**

481 The result of the Deeks' test (p=0.001) shows significant asymmetry in the funnel plot for all datasets
482 with complete results. This indicates there may be publication bias from studies with small sample
483 sizes. However, when looking at publications specifically for LumiraDx (p=0.567), Standard Q
484 (p=0.23), and Panbio (p=0.35), the results do not show significant asymmetry in the funnel plots,

485 indicating these tests may have less publication bias. All funnel plots are listed in the Supplement
486 (S12).
487
488 COMPARISON WITH ANALYTICAL STUDIES
489 The nine analytical studies were divided into 63 data sets, evaluating 23 different Ag-RDTs. Only
490 seven studies reported a samples size, wherein 833 (90.6%) samples originated from NP swabs and
491 for 86 (9.4%) the sample type was unclear. One of the two studies not reporting sample size used
492 saliva samples [198], while the other used the sample type specified in the respective Ag-RDT's IFU
493 [173].
494 Overall, the reported analytical sensitivity (limit of detection) in the studies resembled the re-
495 sults of the meta-analysis presented above. Rapigen (limit of detection (LOD) in log10 copies per
496 swab: 10.2) and Coris (LOD 7.46) were found to perform worse than Panbio (LOD 6.6 to 6.1) and
497 Standard Q (LOD 6.8 to 6.0), whereas the Clinitest (LOD 6.0) and the BinaxNOW by Abbott (LOD 4.6
498 to 4.9) performed even better [191,256,282]. Similar results were found in another study, where the
499 Standard Q showed the lowest LOD (detecting virus up to what is an equivalent Ct-value of 26.3 to
500 28.7), when compared to that of Rapigen and Coris (detecting virus up to what is an equivalent Ct-
501 value of only 18.4 for both) [208,274,275]. However, another study found the Panbio, Standard Q,
502 Coris and BinaxNOW to have a similar LOD of $5.0*10^3$ plaque forming units (pfu) /milliliter (ml), but
503 the ESPLINE SARS-CoV-2 by Fujirebio (Japan), the COVID-19 Rapid Antigen Test by MOLOGIC (United
504 Kingdom) and the Sure Status COVID-19 Antigen Card Test by Premier Medical Corporation (India) to
505 perform markedly better (LOD 2.5 to $5.0*10^2$ pfu/ml) [173]. An overview of all LODs reported in the
506 studies can be found in the Supplement (S13)
507
508 SENSITIVITY ANALYSIS
509 When the data sets from case control studies (25/173) were excluded, the estimated sensitivity
510 did not differ greatly, with a value of 70.9% (95% CI 67.7 to 73.9) compared to 71.2% (95% CI 68.2 to

511 74.0) in the overall analysis with no change in pooled specificity. When excluding the data sets from
512 pre-prints (64/173), sensitivity decreased slightly to 67.2% (95% CI 62.9 to 71.3) compared to the
513 overall analysis.

514 **DISCUSSION**

515 In this comprehensive systematic review and meta-analysis, we have summarized the data of
516 133 studies evaluating the accuracy of 61 different Ag-RDTs. Across all meta-analyzed samples, our
517 results show a pooled sensitivity and specificity of 71.2% (95% CI 68.2 to 74.0) and 98.9% (95% CI
518 98.6 to 99.1). Over half of the studies did not perform the Ag-RDT in accordance with the test manu-
519 facturers' recommendation or the performance was unknown, which negatively impacted the sensi-
520 tivity. When considering only IFU-conforming studies, the sensitivity increased to 76.3% (95% CI 73.1
521 to 79.2). While we found the sensitivity to vary across specific tests, the specificity was consistently
522 high.

523

524 The two Ag-RDTs that have been approved through the WHO emergency use listing procedure,
525 Abbott Panbio and SD Biosensor Standard Q (distributed by Roche in Europe), have not only drawn
526 the largest research interest, but also perform at or above average when comparing their pooled
527 accuracy to that of all Ag-RDTs (sensitivity of 71.8% for Panbio and of 74.9% for Standard Q). The
528 Standard Q nasal demonstrated an even higher pooled sensitivity (80.2% compared to the NP test),
529 although this is likely due to variability in populations tested, as head-to-head performance showed a
530 comparable sensitivity. Three other Ag-RDTs showed an even higher accuracy with sensitivities rang-
531 ing from 77.4% to 88.2% (namely Sofia, Lumipulse G and LumiraDX), but were only assessed on rela-
532 tively small samples sizes (ranging from 1,373 to 3,532) and all required an instrument/reader.

533

534 Not surprisingly, lower Ct-values, the RT-PCR semi-quantitative correlate for a high virus con-
535 centration, resulted in a significantly higher Ag-RDT sensitivity than higher Ct-values (pooled sensitivi-
536 ty 96.5% and 95.8% for ct-values <20 and <25 vs. 50.7% and 20.9% for ct-values ≥25 and ≥30). This
537 confirms prior data that suggested that antigen concentrations and Ct-values were highly correlated
538 in NP samples [16]. Ag-RDTs also showed a higher sensitivity in patients within 7 days after symptom
539 onset compared to patients later in the course of the disease (pooled sensitivity 83.8% vs. 61.5%),

540 which is to be expected given that samples from patients within the first week after symptom onset
541 have been shown to contain the highest virus concentrations [297]. In line with this, studies reporting
542 an unexpectedly low overall sensitivity either shared a small population size with an on average high
543 Ct-value [230,273,288] or performed the Ag-RDT not as per IFU, e.g., using saliva or prediluted sam-
544 ples [167,170,203,248,279]. In contrast, studies with an unusually high Ag-RDT sensitivity were based
545 on study populations with a low median Ct-value, between 18 and 22 [189,255,284].

546 Our analysis also found that the accuracy of Ag-RDTs is substantially higher in symptomatic pa-
547 tients than in asymptomatic (pooled sensitivity 76.7% vs. 52.5%). This is not surprising as studies that
548 enrolled symptomatic patients showed a lower range of median Ct-values (i.e., higher viral load),
549 than studies enrolling asymptomatic patients. Given that other studies found symptomatic and
550 asymptomatic patients to have comparable viral loads [298,299], the differences found in our analy-
551 sis are likely explained by the varied time in the course of the disease at which testing is performed in
552 asymptomatic patients presenting for one-time screening testing. As symptoms start in the early
553 phase of the disease when viral load is still high, studies testing only symptomatic patients have a
554 higher chance of including patients with high viral loads. In contrast, study populations drawn from
555 asymptomatic patients only have a higher chance of including patients at any point of disease (i.e.,
556 including late in disease, when PCR is still positive, but viable virus is rapidly decreasing) [300].

557 With regards to the sampling and testing procedure, we found Ag-RDTs to perform similarly
558 across upper-respiratory swab samples (e.g., NP and AN/MT), particularly when considering the most
559 reliable comparisons from head-to-head studies.

560 Similar to previous assessment [7], the methodological quality of the included studies revealed a
561 very heterogenous picture. In the future, aligning the design of clinical accuracy studies to common
562 agreed upon minimal specifications (e.g., by WHO or European Center of Disease Control) and re-
563 porting the results in a standardized way [301] would improve data quality and comparability.

564

565 The main strengths of our study lie in its comprehensive approach and continuous updates. By
566 linking this review to our website www.diagnosticsglobalhealth.org, we strive to equip decision mak-
567 ers with the latest research findings on Ag-RDTs for SARS-CoV-2 and, to the best of our knowledge,
568 are the first in doing so. At least once per week the website is updated by continuing the literature
569 search and process described above. We plan to update the meta-analysis on a monthly basis and
570 publish it on the website. Furthermore, our study used rigorous methods as both the study selection
571 and data extraction were performed by one author and independently validated by a second, we
572 conducted blinded pilot extractions before of the actual data extraction, and we prepared a detailed
573 interpretation guide for the QUADAS-2 tool.

574 The study may be limited by the inclusion of both preprints and peer-reviewed literature, which
575 could affect the quality of the data extracted. However, we aimed to balance this potential effect by
576 applying a thorough assessment of all clinical studies included, utilizing the QUADAS-2 tool and per-
577 forming a sensitivity analysis excluding preprint manuscripts. In addition, the studies included in our
578 analysis varied widely in the reported range of viral loads, limiting the comparability of their results.
579 To control for this, we analyzed the Ag-RDTs' performance at different levels of viral load. Finally,
580 even though we are aware that further data exits from other sources, for example from governmen-
581 tal research institutes exists [302], such data could not be included as sufficient detail describing the
582 methods and results are not publicly available.

583 **CONCLUSION**

584 In summary, it can be concluded that there are Ag-RDTs available that have high sensitivity, par-
585 ticularly when performed in the first week of illness when viral load is high, and excellent specificity.
586 However, our analysis also highlights the variability in results between tests (which is not reflected in
587 the manufacturer reported data), indicating the need for independent validations. Furthermore, the
588 analysis highlights the importance of performing tests in accordance with the manufacturers' rec-
589 ommended procedures, and in alignment with standard diagnostic evaluation and reporting guide-
590 lines. The accuracy achievable by the best-performing Ag-RDTs, combined with the rapid turn-around
591 time compared to RT-PCR, suggests that these tests could have a significant impact on the pandemic
592 if applied in thoughtful testing and screening strategies.

SOURCES

1. World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays: interim guid-ance, 11 September 2020. No WHO/2019-nCoV/Antigen_Detection/20201, 2020b.
2. Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity - A Strategy for Containment. New England Journal of Medicine, 2020; 383(22). DOI:10.1056/NEJMp2025631.
3. Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte). Liste der Antigen-Tests zum direkten Erregernachweis des Coronavirus SARS-CoV-2 2021 [Available from: https://www.bfarm.de/DE/Medizinprodukte/Antigentests/_node.html, accessed on June 07, 2021.
4. Krüger LJ, Gaeddert M, Köppel L, Brümmer LE, Gottschalk C, Miranda IB, et al. Evaluation of the accuracy, ease of use and limit of detection of novel, rapid, antigen-detecting point-of-care diagnostics for SARS-CoV-2. medRxiv [Preprint]; published October 04, 2020. DOI:10.1101/2020.10.01.20203836.
5. Denkinger CM, Grenier J, Minion J, Pai M. Promise versus reality: optimism bias in package inserts for tuberculosis diagnostics. Journal of Clinical Microbiology, 2012; 50(7):2455-61. DOI:10.1128/JCM.00842-12.
6. World Health Organization. Advice on the use of point-of-care immunodiagnostic tests for COVID-19: scientific brief, 8 April 2020. No WHO/2019-nCoV/Sci_Brief/POC_immunodiagnostics/20201, 2020a.
7. Dinnes J, Deeks JJ, Adriano A, Berhane S, Davenport C, Dittrich S, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection (Review). Cochrane Database of Systematic Reviews, 2020; (8). DOI:10.1002/14651858.Cd013705.
8. Olalekan A, Iwalokun B, Akinloye OM, Popoola O, Samuel TA, Akinloye O. COVID-19 rapid diagnostic test could contain transmission in low- And middle-income countries. African Journal of Laboratory Medicine, 2020; 9(1). DOI:10.4102/ajlm.v9i1.1255.
9. Castro R, Luz PM, Wakimoto MD, Veloso VG, Grinsztejn B, Perazzo H. COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil. Brazilian Journal of Infectious Diseases, 2020; 24(2):180-187. DOI:10.1016/j.bjid.2020.04.003.
10. La Marca A, Capuzzo M, Paglia T, Roli L, Trenti T, Nelson SM. Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays. Reproductive Biomedicine Online, 2020; 41(3):483-499. DOI:10.1016/j.rbmo.2020.06.001.
11. Dinnes J, Deeks JJ, Berhane S, Taylor M, Adriano A, Davenport C, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database of Systematic Reviews, 2021; 3:CD013705. DOI:10.1002/14651858.CD013705.pub2.
12. Van Walle I, Leitmeyer K, Broberg E. Meta-analysis of the clinical performance of commercial SARS-CoV-2 nucleic acid, antigen and antibody tests up to 22 August 2020. medRxiv [Preprint]; published September 18, 2020, 2020. DOI:10.1101/2020.09.16.20195917.
13. Hayer J, Kasapic D, Zemmrich C. Real-world clinical performance of commercial SARS-CoV-2 rapid antigen tests in suspected COVID-19: A systematic meta-analysis of available data as per November 20, 2020. medRxiv [Preprint]; published December 24, 2020. DOI:10.1101/2020.12.22.20248614.
14. Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM, Cochrane Diagnostic Test Accuracy Working G. Systematic reviews of diagnostic test accuracy. Annals of Internal Medicine, 2008; 149(12):889-97. DOI:10.7326/0003-4819-149-12-200812160-00008.
15. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of Internal Medicine, 2009; 151(4):264-9, W64. DOI:10.7326/0003-4819-151-4-200908180-00135.
16. Pollock N, Savage T, Wardell H, Lee R, Mathew A, Stengelin M, et al. Correlation of SARS-CoV-2 nucleocapsid antigen and RNA concentrations in nasopharyngeal samples from children and adults

643 using an ultrasensitive and quantitative antigen assay. medRxiv [Preprint]; published November 13,
644 2020. DOI:10.1101/2020.11.10.20227371.
645 17. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a
646 revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine,
647 2011; 155(8):529-36. DOI:10.7326/0003-4819-155-8-201110180-00009.
648 18. van Enst WA, Ochodo E, Scholten RJ, Hooft L, Leeflang MM. Investigation of publication bias
649 in meta-analyses of diagnostic test accuracy: a meta-epidemiological study. BMC Med Research
650 Methodology, 2014; 14:70. DOI:10.1186/1471-2288-14-70.
651 19. Courtellemont L, Guinard J, Guillaume C, Giaché S, Rzepecki V, Seve A, et al. Real-life
652 performance of a novel antigen detection test on nasopharyngeal specimens for SARS-CoV-2
653 infection diagnosis: a prospective study. medRxiv [Preprint]; published November 3, 2020.
654 DOI:10.1101/2020.10.28.20220657.
655 20. Diao B, Wen K, Chen J, Liu Y, Yuan Z, Han C, et al. Diagnosis of Acute Respiratory Syndrome
656 Coronavirus 2 Infection by Detection of Nucleocapsid Protein. medRxiv [Preprint]; published March
657 13, 2020. DOI:10.1101/2020.03.07.20032524.
658 21. Foundation for Innovative New Diagnostics. FIND Evaluation of Abbott Panbio COVID-19 Ag
659 Rapid Test Device. External Report Version 21, 10 December, 2020.
660 22. Foundation for Innovative New Diagnostics. FIND Evaluation of Coris BioConcept COVID-19
661 Ag Respi-Strip. External Report Version 12, 10 December, 2020.
662 23. Foundation for Innovative New Diagnostics. FIND Evaluation of Shenzhen Bioeasy
663 Biotechnology Co. Ltd. 2019-nCoV Ag Rapid Test Kit (Fluorescence). External Report Version 10, 11
664 February 2021, 2021.
665 24. Ikeda M, Imai K, Tabata S, Miyoshi K, Mizuno T, Murahara N, et al. Clinical evaluation of self-
666 collected saliva by RT-qPCR, direct RT-qPCR, RT-LAMP, and a rapid antigen test to diagnose COVID-
667 19. medRxiv [Preprint]; published June 08, 2020. DOI:10.1101/2020.06.06.20124123.
668 25. Klein JAF, Krüger L, Tobian F, Gaeddert M, Lainati F, Schnitzler P, et al. Head-to-head
669 performance comparison of self-collected nasal versus professional-collected nasopharyngeal swab
670 for a WHO-listed SARS-CoV-2 antigen-detecting rapid diagnostic test. medRxiv [Preprint]; published
671 March 24, 2021. DOI:10.1101/2021.03.17.21253076.
672 26. Masiá M, Fernández-González M, Sánchez M, Carvajal M, García JA, Gonzalo N, et al.
673 Nasopharyngeal Panbio COVID-19 antigen performed at point-of-care has a high sensitivity in
674 symptomatic and asymptomatic patients with higher risk for transmission and older age. medRxiv
675 [Preprint]; published November 17, 2020. DOI:10.1101/2020.11.16.20230003.
676 27. Weitzel T, Legarraga P, Iruretagoyena M, Pizarro G, Vollrath V, Araos R, et al. Head-to-head
677 comparison of four antigen-based rapid detection tests for the diagnosis of SARS-CoV-2 in respiratory
678 samples. bioRxiv [Preprint]; published May 30, 2020. DOI:10.1101/2020.05.27.119255.
679 28. Peeling RW, Olliaro P. Rolling out COVID-19 antigen rapid diagnostic tests: the time is now.
680 Lancet Infectious Diseases, 2021; online first. DOI:10.1016/s1473-3099(21)00152-3.
681 29. Cui Z, Chang H, Wang H, Lim B, Hsu CC, Yu Y, et al. Development of a rapid test kit for SARS-
682 CoV-2: an example of product design. Bio-Design and Manufacturing, 2020:1-4. DOI:10.1007/s42242-
683 020-00075-7.
684 30. Ndwandwe D, Mathebula L, Kamadjeu R, Wiysonge CS. Cochrane corner: rapid point-of-care
685 antigen and molecular-based tests for the diagnosis of COVID-19 infection. The Pan African Medical
686 Journal, 2020; 37(Suppl 1):10. DOI:10.11604/pamj.supp.2020.37.10.25982.
687 31. Pavelka M, Van-Zandvoort K, Abbott S, Sherratt K, Majdan M, Jarčuška P, et al. The
688 effectiveness of population-wide, rapid antigen test based screening in reducing SARS-CoV-2
689 infection prevalence in Slovakia. medRxiv [Preprint]; published December 04,, 2020.
690 DOI:10.1101/2020.12.02.20240648.
691 32. Ebrahimi M, Harmooshi NN, Rahim F. Diagnostic Utility of Antigen Detection Rapid Diagnostic
692 Tests for Covid- 19: A Systematic Review and Meta-Analysis. medRxiv [Preprint]; published April 05,
693 2021. DOI:10.1101/2021.04.02.21254714.

694 33. Everitt ML, Tillery A, David MG, Singh N, Borison A, White IM. A critical review of point-of-
695 care diagnostic technologies to combat viral pandemics. Analytica Chimica Acta, 2021; 1146:184-199.
696 DOI:10.1016/j.aca.2020.10.009.
697 34. Hledík M, Polechová J, Beiglböck M, Herdina AN, Strassl R, Posch M. Analysis of the specificity
698 of the SD Biosensor Standard Q Ag-Test based on Slovak mass testing data. medRxiv [Preprint];
699 published December 11, 2020. DOI:10.1101/2020.12.08.20246090.
700 35. Huergo MAC, Thanh NTK. Current advances in the detection of COVID-19 and evaluation of
701 the humoral response. Analyst, 2021; 146:382-402. DOI:10.1039/d0an01686a.
702 36. Laghrib F, Saqrane S, El Bouabi Y, Farahi A, Bakasse M, Lahrich S, et al. Current progress on
703 COVID-19 related to biosensing technologies: New opportunity for detection and monitoring of
704 viruses. Microchemical Journal, 2021; 160:105606. DOI:10.1016/j.microc.2020.105606.
705 37. Maddali H, Miles CE, Kohn J, O'Carroll DM. Optical Biosensors for Virus Detection: Prospects
706 for SARS-CoV-2/COVID-19. Chembiochem, 2021; 22(7):1176-1189. DOI:10.1002/cbic.202000744.
707 38. Marchán-López Á, García BA. Diagnostic performance of antigen testing for SARS-CoV-2. The
708 Journal of Pediatrics, 2021; 233:283. DOI:10.1016/j.jpeds.2021.02.052.
709 39. McDermott JH, Stoddard D, Ellingford JM, Gokhale D, Reynard C, Black G, et al. Utilizing
710 point-of-care diagnostics to minimize nosocomial infection in the 2019 novel coronavirus (SARS-CoV-
711 2) pandemic. QJM: An International Journal of Medicine, 2020; 113(12):851-853.
712 DOI:10.1093/qjmed/hcaa185.
713 40. Moreira V, Mascarenhas P, Machado V, Botelho J, Mendes JJ, Taveira N, et al. Diagnosis of
714 SARS-Cov-2 infection using specimens other than naso- and oropharyngeal swabs: a systematic
715 review and meta-analysis. Diagnostics, 2021; 11:363. DOI:10.1101/2021.01.19.21250094.
716 41. Nimmo C, Agbetile J, Bhowmik A, Capocci S, Rajakulasingam RK. Implementing rapid
717 diagnostics for COVID-19. The Lancet Respiratory Medicine, 2021; 9(1):e7. DOI:10.1016/s2213-
718 2600(20)30526-9.
719 42. Raimann FJ, Piekarski F, Adam EH, Zacharowski K, Neef V. Safety considerations for the use of
720 Point-Of-Care diagnostics during SARS-CoV-2 pandemic. Journal of Clinical Laboratory Analysis, 2021;
721 35(1):e23631. DOI:10.1002/jcla.23631.
722 43. Razmy AM, Junaideen SM. Issues of Random Sampling with Rapid Antigen Tests for COVID-19
723 Diagnosis: A Special Reference to Kalmunai RDHS Division. medRxiv [Preprint]; published January 20,
724 2021. DOI:10.1101/2021.01.11.21249636.
725 44. Salcedo N, Harmon A, Herrera BB. Pooling of samples for SARS-CoV-2 detection using rapid
726 antigen tests. medRxiv [Preprint]; published February 12, 2021. DOI:10.1101/2021.02.09.21250610.
727 45. Sanderlin JS, Golding JD, Wilcox T, Mason DH, McKelvey KS, Pearson DE, et al. Occupancy
728 modeling and resampling overcomes low test sensitivity to produce accurate SARS-CoV-2 prevalence
729 estimates. BMC Public Health, 2021; 21(1):577. DOI:10.1186/s12889-021-10609-y.
730 46. Scheier T, Schibli A, Eich G, Rüegg C, Kube F, Schmid A, et al. Universal Admission Screening
731 for SARS-CoV-2 Infections among Hospitalized Patients, Switzerland, 2020. Emerging Infectious
732 Diseases, 2021; 27(2). DOI:10.3201/eid2702.202318.
733 47. Stovitz SD. In suspected SARS-CoV-2, rapid antigen detection tests had 67% to 73% sensitivity
734 and 98% to 100% specificity. Annals of Internal Medicine, 2021; 174:JC56.
735 DOI:10.7326/acpj202105180-056.
736 48. van Beek J, Igloi Z, Boelsums T, Fanoy E, Gotz H, Molenkamp R, et al. From more testing to
737 smart testing: data-guided SARS-CoV-2 testing choices. medRxiv [Preprint]; published October 14,
738 2020. DOI:10.1101/2020.10.13.20211524.
739 49. Weiss G, Bellmann-Weiler R. Rapid antigen testing and non-infectious shedding of SARS-
740 Cov2. Infection, 2021; epub ahead of print. DOI:10.1007/s15010-020-01570-w.
741 50. Ehrenberg A, Moehle E, Brook C, Doudna Cate A, Witkowsky L, Sachdeva R, et al. Launching a
742 saliva-based SARS-CoV-2 surveillance testing program on a university campus. medRxiv [Preprint];
743 published January 30, 2021. DOI:10.1101/2021.01.24.21250385.

744 51. Boďová K, Kollár R. Characteristic spatial scales of SARS-CoV-2 pandemics: lessons from mass
745 rapid antigen testing in Slovakia. medRxiv [Preprint]; published December 24, 2020.
746 DOI:10.1101/2020.12.23.20248808.
747 52. Canadian Public Health Laboratory Network. Interim guidance on the use of the Abbott
748 Panbio™ COVID-19 Antigen Rapid Test. Canada Communicable Disease Report, 2021; 47(1):17-22.
749 DOI:10.14745/ccdr.v47i01a04.
750 53. Crozier A, Rajan S, Buchan I, McKee M. Put to the test: use of rapid testing technologies for
751 covid-19. British Medical Journal, 2021; 372:n208. DOI:10.1136/bmj.n208.
752 54. D'Agostino McGowan L, Lee E, Grantz K, Kucirka L, Gurley E, Lessler J. Testing out of
753 quarantine. medRxiv [Preprint]; published 01, 2021. DOI:10.1101/2021.01.29.21250764.
754 55. editorial. Rapid and frequent testing. Nature Biomedical Engineering, 2020; 4(12):1121-1122.
755 DOI:10.1038/s41551-020-00670-0.
756 56. Fitzpatrick MC, Pandey A, Wells CR, Sah P, Galvani AP. Buyer beware: inflated claims of
757 sensitivity for rapid COVID-19 tests. Lancet, 2021; 397(10268):24-25. DOI:10.1016/s0140-
758 6736(20)32635-0.
759 57. Frnda J, Durica M. On Pilot Massive COVID-19 Testing by Antigen Tests in Europe. Case Study:
760 Slovakia. Infectious Disease Reports, 2021; 13(1):45-57. DOI:10.3390/idr13010007.
761 58. Ghaffari A, Meurant R, Ardakani A. COVID-19 Point-of-Care Diagnostics That Satisfy Global
762 Target Product Profiles. Diagnostics, 2021; 11(1). DOI:10.3390/diagnostics11010115.
763 59. Ruhan A, Wang H, Wang W, Tan W. Summary of the Detection Kits for SARS-CoV-2 Approved
764 by the National Medical Products Administration of China and Their Application for Diagnosis of
765 COVID-19. Virologica Sinica, 2020; 35:699-712. DOI:10.1007/s12250-020-00331-1.
766 60. Abdelrazik AM, Elshafie SM, Abdelaziz HM. Potential Use of Antigen-Based Rapid Test for
767 SARS-CoV-2 in Respiratory Specimens in Low-Resource Settings in Egypt for Symptomatic Patients
768 and High-Risk Contacts. Laboratory Medicine, 2020; 52:e46-e49. DOI:10.1093/labmed/lmaa104.
769 61. Aoki K, Nagasawa T, Ishii Y, Yagi S, Okuma S, Kashiwagi K, et al. Clinical validation of
770 quantitative SARS-CoV-2 antigen assays to estimate SARS-CoV-2 viral loads in nasopharyngeal swabs.
771 Journal of Infection and Chemotherapy, 2020; 27(4):613-6. DOI:10.1016/j.jiac.2020.11.021.
772 62. Bonde J, Ejegod D, Pedersen H, Smith B, Cortes D, Leding C, et al. Clinical validation of point-
773 of-care SARS-COV-2 BD Veritor antigen test by a single throat swab for rapid COVID-19 status on
774 hospital patients predominantly without overt COVID symptoms. medRxiv [Preprint]; published April
775 17, 2021. DOI:10.1101/2021.04.12.21255299.
776 63. Boum Y, Fai KN, Nicolay B, Mboringong AB, Bebell LM, Ndifon M, et al. Performance and
777 operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic
778 and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study. Lancet
779 Infectious Diseases, 2021; online first. DOI:10.1016/s1473-3099(21)00132-8.
780 64. Courtellemont L, Guinard J, Guillaume C, Giaché S, Rzepecki V, Seve A, et al. High
781 performance of a novel antigen detection test on nasopharyngeal specimens for diagnosing SARS-
782 CoV-2 infection. Journal of Medical Virology, 2021; 93(5):3152-3157. DOI:10.1002/jmv.26896.
783 65. Eshghifar N, Busheri A, Shrestha R, Beqaj S. Evaluation of Analytical Performance of Seven
784 Rapid Antigen Detection Kits for Detection of SARS-CoV-2 Virus. International Journal of General
785 Medicine, 2021; 14:435-440. DOI:10.2147/ijgm.S297762.
786 66. Hingrat QL, Visseaux B, Laouenan C, Tubiana S, Bouadma L, Yazdanpanah Y, et al. Detection
787 of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new
788 testing alternatives. Clinical Microbiology and Infection, 2020. DOI:10.1016/j.cmi.2020.11.025.
789 67. Kobayashi R, Murai R, Asanuma K, Fujiya Y, Takahashi S. Evaluating a novel, highly sensitive,
790 and quantitative reagent for detecting SARS-CoV-2 antigen. Journal of Infection and Chemotherapy,
791 2021; 27(6):800-807. DOI:10.1016/j.jiac.2021.01.007.
792 68. Kritikos A, Caruana G, Brouillet R, Miroz J-P, Samia A-M, Geraldine S, et al. Sensitivity of rapid
793 antigen testing and RT-PCR performed on nasopharyngeal swabs versus saliva samples in COVID-19
794 hospitalized patients: results of a prospective comparative trial (RESTART). medRxiv [Preprint];
795 published April 15, 2021. DOI:10.1101/2021.04.09.21255105.

796 69. Lanser L, Bellmann-Weiler R, Öttl KW, Huber L, Griesmacher A, Theurl I, et al. Evaluating the
797 clinical utility and sensitivity of SARS-CoV-2 antigen testing in relation to RT-PCR Ct values. Infection,
798 2020:1-3. DOI:10.1007/s15010-020-01542-0.
799 70. Lv Y, Ma Y, Si Y, Zhu X, Zhang L, Feng H, et al. Rapid SARS-CoV-2 antigen detection potentiates
800 early diagnosis of COVID-19 disease. Bioscience Trends, 2021; 15(2):93-99.
801 DOI:10.5582/bst.2021.01090.
802 71. Miyakawa K, Funabashi R, Yamaoka Y, Jeremiah SS, Katada J, Wada A, et al. SARS-CoV-2
803 antigen rapid diagnostic test enhanced with silver amplification technology. medRxiv [Preprint];
804 published January 31, 2021. DOI:10.1101/2021.01.27.21250659.
805 72. Nagura-Ikeda M, Imai K, Tabata S, Miyoshi K, Murahara N, Mizuno T, et al. Clinical Evaluation
806 of Self-Collected Saliva by Quantitative Reverse Transcription-PCR (RT-qPCR), Direct RT-qPCR,
807 Reverse Transcription-Loop-Mediated Isothermal Amplification, and a Rapid Antigen Test To
808 Diagnose COVID-19. Journal of Clinical Microbiology, 2020; 58(9). DOI:10.1128/jcm.01438-20.
809 73. Oh SM, Jeong H, Chang E, Choe PG, Kang CK, Park WB, et al. Clinical Application of the
810 Standard Q COVID-19 Ag Test for the Detection of SARS-CoV-2 Infection. Journal of Korean Medical
811 Science, 2021; 36(14):e101. DOI:10.3346/jkms.2021.36.e101.
812 74. Peña-Rodrígez M, Viera-Segura O, García-Chagollán M, Zepeda-Nuño JS, Muñoz-Valle JF,
813 Mora-Mora J, et al. Performance evaluation of a lateral flow assays for nasopharyngeal antigen
814 detection for SARS-CoV-2 diagnosis. Journal of Clinical Laboratory Analysis, 2021; 35:e23745.
815 DOI:10.1002/jcla.23745.
816 75. Regev-Yochay G, Kriger O, Beni S, Rubin C, Mina M, Mechnik B, et al. Real World Performance
817 of SARS-CoV-2 Antigen Rapid Diagnostic Tests in Various Clinical Settings. medRxiv [Preprint];
818 published March 05, 2021. DOI:10.1101/2021.03.02.21252400.
819 76. Ren A, Sohaei D, Zacharioudakis I, Sigal G, Stengelin M, Matthew A, et al. Ultrasensitive assay
820 for saliva-based SARS-CoV-2 antigen detection. medRxiv [Preprint]; published February 19, 2021.
821 DOI:10.1101/2021.02.17.21251863.
822 77. Rodrigues J, Gouveia C, Santos MA, Costa O, Côrte-Real R, Brito MJ. Comparison of
823 nasopharyngeal samples for SARS-CoV-2 detection in a paediatric cohort. Journal of Paediatrics and
824 Child Health, 2021; online ahead of print. DOI:10.1111/jpc.15405.
825 78. Saeed U, Uppal SR, Piracha ZZ, Rasheed A, Aftab Z, Zaheer H, et al. Evaluation of SARS-CoV-2
826 antigen-based rapid diagnostic kits in Pakistan: formulation of COVID-19 national testing strategy.
827 Virology Journal, 2021; 18(1):34. DOI:10.1186/s12985-021-01505-3.
828 79. Smith R, Gibson L, Martinez P, Ke R, Mirza A, Conte M, et al. Longitudinal assessment of
829 diagnostic test performance over the course of acute SARS-CoV-2 infection. medRxiv [Preprint];
830 published March 22, 2021. DOI:10.1101/2021.03.19.21253964.
831 80. Stokes W, Berenger B, Portnoy D, Scott B, Szelewicki J, Singh T, et al. Real-World Clinical
832 Performance of the Abbott Panbio with Nasopharyngeal, Throat and Saliva Swabs Among
833 Symptomatic Individuals with COVID-19. European Journal of Clinical Microbiology & Infectious
834 Diseases, 2021; online ahead of print. DOI:10.1101/2021.01.02.21249138.
835 81. Thommes L, Burkert FR, Öttl KW, Goldin D, Loacker L, Lanser L, et al. Comparative evaluation
836 of four SARS-CoV-2 antigen tests in hospitalized patients. International Journal of Infectious Diseases,
837 2021; 105:144–146. DOI:10.1016/j.ijid.2021.02.052.
838 82. Yokota I, Sakurazawa T, Sugita J, Iwasaki S, Yasuda K, Yamashita N, et al. Performance of
839 qualitative and quantitative antigen tests for SARS-CoV-2 in early symptomatic patients using saliva.
840 medRxiv [Preprint]; published November 10, 2020. DOI:10.1101/2020.11.06.20227363.
841 83. Zacharias M, Stangl V, Thüringer A, Loibner M, Wurm P, Wolfgruber S, et al. Rapid Antigen
842 Test for Postmortem Evaluation of SARS-CoV-2 Carriage. Emerging Infectious Diseases, 2021; 27(6).
843 DOI:10.3201/eid2706.210226.
844 84. Apostolou T, Kyritsi M, Vontas A, Loizou K, Hadjilouka A, Speletas M, et al. Development and
845 performance characteristics evaluation of a new Bioelectric Recognition Assay (BERA) method for
846 rapid Sars-CoV-2 detection in clinical samples. Journal of Virological Methods, 2021; 293:114166.
847 DOI:10.1016/j.jviromet.2021.114166.

848 85. Arnaout R, Lee RA, Lee GR, Callahan C, Cheng A, Yen CF, et al. The Limit of Detection Matters:
849 The Case for Benchmarking Severe Acute Respiratory Syndrome Coronavirus 2 Testing. Clinical
850 Infectious Diseases, 2021; ciaa1382. DOI:10.1093/cid/ciaa1382.
851 86. Cheah PK, Ongkili DF, Zaharuddin FS, Hashim MI, Ho CV, Lee HG, et al. Discrepancy in
852 Screening Performances of Different Rapid Test Kits for SARS-CoV-2; a Letter to Editor. Archives of
853 Academic Emergency Medicine, 2021; 9(1):e9. DOI:10.22037/aaem.v9i1.1045.
854 87. Doron S, Ingalls R, Beauchamp A, Boehm J, Boucher H, Chow L, et al. Weekly SARS-CoV-2
855 screening of asymptomatic students and staff to guide and evaluate strategies for safer in-person
856 learning. medRxiv [Preprint]; published March 22, 2021. DOI:10.1101/2021.03.20.21253976.
857 88. Grossi E, Agnoli B, Baldini M, Illari S, Bonini R, Scagnelli G. Universal Sars-Cov-2 Screening in
858 Pregnant Women: Experience from the Italian Epidemic Outbreak. Acta Biomed, 2021;
859 92(S2):e2021001. DOI:10.23750/abm.v92iS2.11320.
860 89. Hicks SM, Pohl K, Neeman T, McNamara HA, Parsons KM, He JS, et al. A Dual-Antigen
861 Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome
862 Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting. Journal of Infectious Diseases,
863 2021; 223(1):10-14. DOI:10.1093/infdis/jiaa623.
864 90. Kiyasu Y, Akashi Y, Sugiyama A, Takeuchi Y, Notake S, Naito A, et al. A prospective evaluation
865 of the analytical performance of GENECUBE® HQ SARS-CoV-2 and GENECUBE® FLU A/B. medRxiv
866 [Preprint]; published February 25, 2021. DOI:10.1101/2021.02.24.21252337.
867 91. Lagi F, Trevisan S, Piccica M, Graziani L, Basile G, Mencarini J, et al. Use of the FebriDx point-
868 of-care test for the exclusion of SARS-CoV-2 diagnosis in a population with acute respiratory infection
869 during the second (COVID-19) wave in Italy. International Journal of Infectious Diseases, 2021; article
870 in press. DOI:10.1016/j.ijid.2021.04.065.
871 92. Latiano A, Tavano F, Panza A, Palmieri O, Niro GA, Andriulli N, et al. False Positive Results Of
872 IgM/IgG antibodies against antigen of the SARS-CoV-2 in sera stored before the 2020 Endemia in
873 Italy. International Journal of Infectious Diseases, 2020; 104:159-163. DOI:10.1016/j.ijid.2020.12.067.
874 93. Li J, Hu X, Wang X, Yang J, Zhang L, Deng Q, et al. A novel One-pot rapid diagnostic technology
875 for COVID-19. Analytica Chimica Acta, 2021; 1154:338310. DOI:10.1016/j.aca.2021.338310.
876 94. Marsic T, Ali Z, Tehseen M, Mahas A, Hamdan S, Mahfouz M. Vigilant: An Engineered VirD2-
877 Cas9 Complex for Lateral Flow Assay-Based Detection of SARS-CoV2. Nano Letters, 2021; 21(8):3596–
878 3603. DOI:10.1021/acs.nanolett.1c00612.
879 95. Schleicher T, Spenlinhauer T, Amadei M, Dasch N, Gordon J, Macleod G, et al. Development
880 of a Multiplexed Synthetic Control for Rapid Detection of SARS-CoV-2 and Other Respiratory
881 Pathogens Using a Nucleic Acid Syndromic Testing Panel. Journal of Molecular Diagnostics, 2020;
882 22(11):S37-S37.
883 96. Bello-Chavolla OY, Antonio-Villa NE, Fernández-Chirino L, Guerra E, Fermín-Martínez C,
884 Márquez-Salinas A, et al. Diagnostic performance and clinical implications of rapid SARS-CoV-2
885 antigen testing in Mexico using real-world nationwide COVID-19 registry data. medRxiv [Preprint];
886 published January 04, 2021. DOI:10.1101/2021.01.02.21249141.
887 97. Dalal A, Sonika U, Kumar M, George R, Kumar A, Srivastava S, et al. COVID-19 Rapid Antigen
888 Test: Role in Screening Prior to Gastrointestinal Endoscopy. Clinical Endoscopy, 2021; online ahead of
889 print. DOI:10.5946/ce.2020.295.
890 98. Downs LO, Eyre DW, O'Donnell D, Jeffery K. Home-based SARS-CoV-2 lateral flow antigen
891 testing in hospital workers. Journal of Infection, 2021; 82(2):282-327. DOI:10.1016/j.jinf.2021.01.008.
892 99. Haage VC, Moreira-Soto A, Sacks J, Corman V, Drosten C, Drexler JF. Limited specificity of
893 SARS-CoV-2 antigen-detecting rapid diagnostic tests at low temperatures. medRxiv [Preprint];
894 published February 03, 2021. DOI:10.1101/2021.02.01.21250904.
895 100. Hoehl S, Schenk B, Rudych O, Göttig S, Foppa I, Kohmer N, et al. At-home self-testing of
896 teachers with a SARS-CoV-2 rapid antigen test to reduce potential transmissions in schools. medRxiv
897 [Preprint]; published December 07, 2020. DOI:10.1101/2020.12.04.20243410.

898 101. Marco A, Solé C, Abdo IJ, Turu E. Low sensitivity of rapid antigenic tests as a screening
899 method in an outbreak of SARS-CoV-2 infection in prison. Enfermedades Infecciosas y Microbiología
900 Clínica, 2021; online ahead of print. DOI:10.1016/j.eimc.2021.01.016.
901 102. Matsuda EM, de Campos IB, de Oliveira IP, Colpas DR, Carmo A, Brígido LFM. Field evaluation
902 of COVID-19 antigen tests versus RNA based detection: Potential lower sensitivity compensated by
903 immediate results, technical simplicity and low cost. Journal of Medical Virology, 2021; 93(7):4405-
904 4410. DOI:10.1002/jmv.26985.
905 103. Moreno G, Braun K, Pray I, Segaloff H, Lim A, Poulson K, et al. SARS-CoV-2 transmission in
906 intercollegiate athletics not fully mitigated with daily antigen testing. medRxiv [Preprint]; published
907 March 06, 2021. DOI:10.1101/2021.03.03.21252838.
908 104. Yamayoshi S, Sakai-Tagawa Y, Koga M, Akasaka O, Nakachi I, Koh H, et al. Comparison of
909 Rapid Antigen Tests for COVID-19. Viruses-Basel, 2020; 12(12). DOI:10.3390/v12121420.
910 105. Yokota I, Shane P, Teshima T. Logistic advantage of two-step screening strategy for SARS-
911 CoV-2 at airport quarantine. medRxiv [Preprint]; published January 26, 2021.
912 DOI:10.1101/2021.01.25.21250509.
913 106. Häuser F, Sprinzl MF, Dreis KJ, Renzaho A, Youhanen S, Kremer WM, et al. Evaluation of a
914 laboratory-based high-throughput SARS-CoV-2 antigen assay for non-COVID-19 patient screening at
915 hospital admission. Medical Microbiology and Immunology, 2021; 201(2-3):165-171.
916 DOI:10.1007/s00430-021-00706-5.
917 107. Colavita F, Vairo F, Meschi S, Valli MB, Lalle E, Castilletti C, et al. COVID-19 Rapid Antigen Test
918 as Screening Strategy at Points of Entry: Experience in Lazio Region, Central Italy, August-October
919 2020. Biomolecules, 2021; 11(3). DOI:10.3390/biom11030425.
920 108. Kotsiou OS, Pantazopoulos I, Papagiannis D, Fradelos EC, Kanellopoulos N, Siachpazidou D, et
921 al. Repeated Antigen-Based Rapid Diagnostic Testing for Estimating the Coronavirus Disease 2019
922 Prevalence from the Perspective of the Workers' Vulnerability before and during the Lockdown.
923 International Journal of Environmental Research and Public Health, 2021; 18(4).
924 DOI:10.3390/ijerph18041638.
925 109. Blairon L, Wilmet A, Beukinga I, Tre-Hardy M. Implementation of rapid SARS-CoV-2 antigenic
926 testing in a laboratory without access to molecular methods: Experiences of a general hospital.
927 Journal of Clinical Virology, 2020; 129:104472. DOI:10.1016/j.jcv.2020.104472.
928 110. Kashiwagi K, Ishii Y, Aoki K, Yagi S, Maeda T, Miyazaki T, et al. Immunochromatographic test
929 for the detection of SARS-CoV-2 in saliva. medRxiv [Preprint]; published May 25, 2020.
930 DOI:10.1101/2020.05.20.20107631.
931 111. Itoh K, Kawamitsu T, Osaka Y, Sato K, Suzuki Y, Kiriba C, et al. False positive results in severe
932 acute respiratory coronavirus 2 (SARS-CoV-2) rapid antigen tests for inpatients. Journal of Infection
933 and Chemotherapy, 2021; 27(7):1089-1091. DOI:10.1016/j.jiac.2021.03.011.
934 112. Prince-Guerra JL, Almendares O, Nolen LD, Gunn JKL, Dale AP, Buono SA, et al. Evaluation of
935 Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing
936 Sites - Pima County, Arizona, November 3-17, 2020. Morbidity and Mortality Weekly Report, 2021;
937 70(3):100-105. DOI:10.15585/mmwr.mm7003e3.
938 113. Aoki K, Nagasawa T, Ishii Y, Yagi S, Kashiwagi K, Miyazaki T, et al. Evaluation of clinical utility
939 of novel coronavirus antigen detection reagent, Espline® SARS-CoV-2. Journal of Infection and
940 Chemotherapy, 2021; 27(2):319-322. DOI:10.1016/j.jiac.2020.11.015.
941 114. Caputo V, Bax C, Colantoni L, Peconi C, Termine A, Fabrizio C, et al. Comparative analysis of
942 antigen and molecular tests for the detection of Sars-CoV-2 and related variants: a study on 4266
943 samples. International Journal of Infectious Diseases, 2021; 21:S1201-9712.
944 DOI:10.1016/j.ijid.2021.04.048.
945 115. Ford L, Lee C, Pray IW, Cole D, Bigouette JP, Abedi GR, et al. Epidemiologic characteristics
946 associated with SARS-CoV-2 antigen-based test results, rRT-PCR cycle threshold values, subgenomic
947 RNA, and viral culture results from university testing. Clinical Infectious Diseases, 2021; ciab303.
948 DOI:10.1093/cid/ciab303.

949 116. Hirotsu Y, Maejima M, Shibusawa M, Nagakubo Y, Hosaka K, Amemiya K, et al. Comparison of
950 automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using 313
951 nasopharyngeal swabs, including from seven serially followed patients. International Journal of
952 Infectious Diseases, 2020; 99:397-402. DOI:10.1016/j.ijid.2020.08.029.
953 117. Ishii T, Sasaki M, Yamada K, Kato D, Osuka H, Aoki K, et al. Immunochromatography and
954 chemiluminescent enzyme immunoassay for COVID-19 diagnosis. Journal of Infection and
955 Chemotherapy, 2021; 27(6):915-918. DOI:10.1016/j.jiac.2021.02.025.
956 118. Kiyasu Y, Takeuchi Y, Akashi Y, Kato D, Kuwahara M, Muramatsu S, et al. Prospective
957 analytical performance evaluation of the QuickNavi™-COVID19 Ag for asymptomatic individuals.
958 medRxiv [Preprint]; published April 07, 2021. DOI:10.1101/2021.04.01.21254813.
959 119. Korenkov M, Poopalasingam N, Madler M, Vanshylla K, Eggeling R, Wirtz M, et al. Reliable
960 assessment of in vitro SARS-CoV-2 infectivity by a Rapid Antigen Detection Test. medRxiv [Preprint];
961 published April 06, 2021. DOI:10.1101/2021.03.30.21254624.
962 120. Kronberg Jakobsen K, Schmidt Jensen J, Todsen T, Lippert F, Jean-Marie Martel C, Klokker M,
963 et al. Detection of SARS-CoV-2 infection by rapid antigen test in comparison with RT-PCR in a public
964 setting. medRxiv [Preprint]; published January 25, 2021. DOI:10.1101/2021.01.22.21250042.
965 121. Kweon OJ, Lim YK, Kim HR, Choi Y, Kim MC, Choi SH, et al. Evaluation of rapid SARS-CoV-2
966 antigen tests, AFIAS COVID-19 Ag and ichroma COVID-19 Ag, with serial nasopharyngeal specimens
967 from COVID-19 patients. PLoS One, 2021; 16(4):e0249972. DOI:10.1371/journal.pone.0249972.
968 122. Landaas ET, Storm ML, Tollånes MC, Barlinn R, Kran AB, Bragstad K, et al. Diagnostic
969 performance of a SARS-CoV-2 rapid antigen test in a large, Norwegian cohort. Journal of Clinical
970 Virology, 2021; 137:104789. DOI:10.1016/j.jcv.2021.104789.
971 123. McAulay K, Kaleta EJ, Grys TE. Rapid Detection of SARS-CoV-2 Antigen from Serum in a
972 Hospitalized Population. medRxiv [Preprint]; published December 22, 2020.
973 DOI:10.1101/2020.12.21.20248140.
974 124. McKay SL, Tobolowsky FA, Moritz ED, Hatfield KM, Bhatnagar A, LaVoie SP, et al.
975 Performance Evaluation of Serial SARS-CoV-2 Rapid Antigen Testing During a Nursing Home
976 Outbreak. Annals of Internal Medicine, 2021; online ahead of print. DOI:10.7326/m21-0422.
977 125. Pray IW, Ford L, Cole D, Lee C, Bigouette JP, Abedi GR, et al. Performance of an Antigen-
978 Based Test for Asymptomatic and Symptomatic SARS-CoV-2 Testing at Two University Campuses -
979 Wisconsin, September-October 2020. Morbidity and Mortality Weekly Report, 2021; 69(5152):1642-
980 1647. DOI:10.15585/mmwr.mm695152a3.
981 126. Rastawicki W, Gierczyński R, Juszczyk G, Mitura K, Henry BM. Evaluation of PCL rapid point of
982 care antigen test for detection of SARS-CoV-2 in nasopharyngeal swabs. Journal of Medical Virology,
983 2021; 93(4):1920-1922. DOI:10.1002/jmv.26765.
984 127. Shah M, Salvatore P, Ford L, Kamitani E, Whaley M, Mitchell K, et al. Performance of Repeat
985 BinaxNOW SARS-CoV-2 Antigen Testing in a Community Setting, Wisconsin, November-December
986 2020. Clinical Infectious Diseases, 2021; online ahead of print. DOI:10.1101/2021.04.05.21254834.
987 128. Uwamino Y, Nagata M, Aoki W, Nakagawa T, Inose R, Yokota H, et al. Accuracy of rapid
988 antigen detection test for nasopharyngeal swab specimens and saliva samples in comparison with
989 RT-PCR and viral culture for SARS-CoV-2 detection. Journal of Infection and Chemotherapy, 2021;
990 27(7):1058-1062. DOI:10.1016/j.jiac.2021.04.010.
991 129. Winkel BMF, Schram E, Gremmels H, Debast S, Schuurman R, Wensing AMJ, et al. Screening
992 for SARS-CoV-2 infection in asymptomatic individuals using the Panbio™ COVID-19 Antigen Rapid
993 Test (Abbott) compared to RT-qPCR. medRxiv [Preprint]; published December 04, 2020.
994 DOI:10.1101/2020.12.03.20243311.
995 130. Yamamoto K, Suzuki M, Yamada G, Sudo T, Nomoto H, Kinoshita N, et al. Utility of the
996 antigen test for coronavirus disease 2019: Factors influencing the prediction of the possibility of
997 disease transmission. International Journal of Infectious Diseases, 2021; 104:65-72.
998 DOI:10.1016/j.ijid.2020.12.079.

131. Ahava M, Kurkela S, Kuivanen S, Lappalainen M, Jarva H, Jaaskelainen A. Detection of SARS-CoV-2 nucleocapsid antigen from serum can aid in timing of COVID-19 infection. medRxiv [Preprint]; published January 13, 2021. DOI:10.1101/2021.01.08.20248771.
132. Azzi L, Baj A, Alberio T, Lualdi M, Veronesi G, Carcano G, et al. Rapid Salivary Test suitable for a mass screening program to detect SARS-CoV-2: A diagnostic accuracy study. Journal of Infection, 2020; 81(3):E75-E78. DOI:10.1016/j.jinf.2020.06.042.
133. Barauna VG, Singh MN, Barbosa LL, Marcarini WD, Vassallo PF, Mill JG, et al. Ultrarapid On-Site Detection of SARS-CoV-2 Infection Using Simple ATR-FTIR Spectroscopy and an Analysis Algorithm: High Sensitivity and Specificity. Analytical Chemistry, 2021; 93(5):2950–2958. DOI:10.1021/acs.analchem.0c04608.
134. Barlev-Gross M, Weiss S, Ben-Shmuel A, Sittner A, Eden K, Mazuz N, et al. Spike vs nucleocapsid SARS-CoV-2 antigen detection: application in nasopharyngeal swab specimens. Analytical and Bioanalytical Chemistry, 2021; 413:3501–3510. DOI:10.1101/2021.03.08.21253148.
135. Cardozo KHM, Lebkuchen A, Okai GG, Schuch RA, Viana LG, Olive AN, et al. Establishing a mass spectrometry-based system for rapid detection of SARS-CoV-2 in large clinical sample cohorts. Nature Communications, 2020; 11(1):6201. DOI:10.1038/s41467-020-19925-0.
136. Cazares LH, Chaerkady R, Samuel Weng SH, Boo CC, Cimbro R, Hsu HE, et al. Development of a Parallel Reaction Monitoring Mass Spectrometry Assay for the Detection of SARS-CoV-2 Spike Glycoprotein and Nucleoprotein. Analytical Chemistry, 2020; 92(20):13813-13821. DOI:10.1021/acs.analchem.0c02288.
137. Chen H, Li Z, Feng S, Wang A, Richard-Greenblatt M, Hutson E, et al. Femtomolar SARS-CoV-2 Antigen Detection Using the Microbubbling Digital Assay with Smartphone Readout Enables Antigen Burden Quantitation and Dynamics Tracking. medRxiv [Preprint]; published March 26, 2021. DOI:10.1101/2021.03.17.21253847.
138. Colavita F, Vairo F, Meschi S, Valli B, Lalle E, Castilletti C, et al. COVID-19 Antigen Rapid Test as Screening Strategy at the Points-of-Entry: Experience in Lazio Region, Central Italy, August-October 2020. medRxiv [Preprint]; published November 30, 2020. DOI:10.1101/2020.11.26.20232728.
139. Conzelmann C, Gilg A, Groß R, Schütz D, Preising N, Ständker L, et al. An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection. Antiviral Research, 2020; 181:104882. DOI:10.1016/j.antiviral.2020.104882.
140. Di Domenico M, De Rosa A, Boccellino M. Detection of SARS-COV-2 Proteins Using an ELISA Test. Diagnostics (Basel), 2021; 11(4). DOI:10.3390/diagnostics11040698.
141. Diao B, Wen K, Zhang J, Chen J, Han C, Chen Y, et al. Accuracy of a nucleocapsid protein antigen rapid test in the diagnosis of SARS-CoV-2 infection. Clinical Microbiology and Infection, 2020; 27(2):289.e1-289.e4. DOI:10.1016/j.cmi.2020.09.057.
142. Ducrest PJ. Development and Evaluation of a new Swiss Made SARS-CoV-2 antigen-detecting rapid test. medRxiv [Preprint]; published March 26, 2021. DOI:10.1101/2021.03.25.21252280.
143. Grant BD, Anderson CE, Williford JR, Alonzo LF, Glukhova VA, Boyle DS, et al. SARS-CoV-2 Coronavirus Nucleocapsid Antigen-Detecting Half-Strip Lateral Flow Assay Toward the Development of Point of Care Tests Using Commercially Available Reagents. Analytical Chemistry, 2020; 92(16):11305-11309. DOI:10.1021/acs.analchem.0c01975.
144. Huang L, Ding L, Zhou J, Chen S, Chen F, Zhao C, et al. One-step rapid quantification of SARS-CoV-2 virus particles via low-cost nanoplasmonic sensors in generic microplate reader and point-of-care device. Biosensors and Bioelectronics, 2021; 171:112685. DOI:10.1016/j.bios.2020.112685.
145. Kyosei Y, Namba M, Yamura S, Takeuchi R, Aoki N, Nakaishi K, et al. Proposal of De Novo Antigen Test for COVID-19: Ultrasensitive Detection of Spike Proteins of SARS-CoV-2. Diagnostics, 2020; 10(8). DOI:10.3390/diagnostics10080594.
146. Lee JH, Choi M, Jung Y, Lee SK, Lee CS, Kim J, et al. A novel rapid detection for SARS-CoV-2 spike 1 antigens using human angiotensin converting enzyme 2 (ACE2). Biosensors and Bioelectronics, 2021; 171:112715. DOI:10.1016/j.bios.2020.112715.

1049 147. Lee L, Liu F, Chen Y, Roma G. Quantitative and Ultrasensitive In-situ Immunoassay Technology
1050 for SARS-CoV-2 Detection in Saliva. Research Square [Preprint]; published January 18, 2021.
1051 DOI:10.21203/rs.3.rs-138025/v1.
1052 148. Li Y, Peng Z, Holl NJ, Hassan MR, Pappas JM, Wei C, et al. MXene-Graphene Field-Effect
1053 Transistor Sensing of Influenza Virus and SARS-CoV-2. ACS Omega, 2021; 6(10):6643-6653.
1054 DOI:10.1021/acsomega.0c05421.
1055 149. Liu D, Ju C, Han C, Shi R, Chen X, Duan D, et al. Ultra-sensitive nanozyme-based
1056 chemiluminescence paper test for rapid diagnosis of SARS-CoV-2 infection. bioRxiv [Preprint];
1057 published June 05, 2020. DOI:10.1101/2020.06.05.131748.
1058 150. Mahari S, Roberts A, Shahdeo D, Gandhi S. eCovSens-Ultrasensitive Novel In-House Built
1059 Printed Circuit Board Based Electrochemical Device for Rapid Detection of nCovid-19. bioRxiv
1060 [Preprint]; published May 11, 2020. DOI:10.1101/2020.04.24.059204.
1061 151. Nash B, Badea A, Reddy A, Bosch M, Salcedo N, Gomez AR, et al. The impact of high
1062 frequency rapid viral antigen screening on COVID-19 spread and outcomes: a validation and
1063 modeling study. medRxiv [Preprint]; published November 04, 2020.
1064 DOI:10.1101/2020.09.01.20184713.
1065 152. Renuse S, Vanderboom P, Maus A, Kemp J, Gurtner K, Madugundu A, et al. Development of
1066 mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from
1067 clinical specimens. medRxiv [Preprint]; published August 06, 2020.
1068 DOI:10.1101/2020.08.05.20168948.
1069 153. Ricks S, Kendall E, Dowdy D, Sacks J, Schumacher S, Arinaminpathy N. Quantifying the
1070 potential value of antigen-detection rapid diagnostic tests for COVID-19: a modelling analysis. BMC
1071 Medicine, 2020; 19:75. DOI:10.1101/2020.11.20.20235317.
1072 154. Seo G, Lee G, Kim MJ, Baek SH, Choi M, Ku KB, et al. Rapid Detection of COVID-19 Causative
1073 Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based
1074 Biosensor. American Chemical Society, 2020; 14(4):5135-5142. DOI:10.1021/acsnano.0c02823.
1075 155. Shao W, Shurin MR, Wheeler SE, He X, Star A. Rapid Detection of SARS-CoV-2 Antigens Using
1076 High-Purity Semiconducting Single-Walled Carbon Nanotube-Based Field-Effect Transistors. ACS
1077 Applied Materials & Interfaces, 2021; 13(8):10321–10327. DOI:10.1021/acsami.0c22589.
1078 156. Singh N, Ray P, Carlin A, Magallanes C, Morgan S, Laurent L, et al. Hitting the diagnostic sweet
1079 spot: Point-of-care SARS-CoV-2 salivary antigen testing with an off-the-shelf glucometer. medRxiv
1080 [Preprint]; published October 02, 2020. DOI:10.1101/2020.09.24.20200394.
1081 157. Singh P, Chakraborty R, Marwal R, Radhakrishan VS, Bhaskar AK, Vashisht H, et al. A rapid and
1082 sensitive method to detect SARS-CoV-2 virus using targeted-mass spectrometry. Journal of Proteins
1083 and Proteomics, 2020:1-7. DOI:10.1007/s42485-020-00044-9 10.1007/s42485-020-00044-9.
1084 158. Torrente-Rodríguez RM, Lukas H, Tu J, Min J, Yang Y, Xu C, et al. SARS-CoV-2 RapidPlex: A
1085 Graphene-based Multiplexed Telemedicine Platform for Rapid and Low-Cost COVID-19 Diagnosis and
1086 Monitoring. Matter, 2020; 3(6):1981–1998. DOI:10.1016/j.matt.2020.09.027.
1087 159. Vadlamani BS, Uppal T, Verma S, Misra M. Functionalized TiO2 nanotube-based
1088 Electrochemical Biosensor for Rapid Detection of SARS-CoV-2. Sensors, 2020; 20(20):5871.
1089 DOI:10.1101/2020.09.07.20190173.
1090 160. Wang H, Hogan CA, Verghese M, Solis D, Sibai M, Huang C, et al. Ultra-sensitive Severe Acute
1091 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antigen Detection for the Diagnosis of
1092 Coronavirus Disease 2019 (COVID-19) in Upper Respiratory Samples. Clinical Infectious Diseases,
1093 2021; ciab063. DOI:10.1093/cid/ciab063.
1094 161. Yakoh A, Pimpitak U, Rengpipat S, Hirankarn N, Chailapakul O, Chaiyo S. Paper-based
1095 electrochemical biosensor for diagnosing COVID-19: Detection of SARS-CoV-2 antibodies and antigen.
1096 Biosensors & Bioelectronics, 2021; 176:112912. DOI:10.1016/j.bios.2020.112912.
1097 162. Zakashansky J, Imamura A, Salgado D, Romero Mercieca H, Aguas RFL, Lao A, et al. Detection
1098 of the SARS-CoV-2 spike protein in saliva with Shrinky-Dink© electrodes. medRxiv [Preprint];
1099 published November 18, 2020. DOI:10.1101/2020.11.14.20231811.

1100 163. Zhang CY, Zhou L, Du K, Zhang Y, Wang J, Chen LJ, et al. Foundation and Clinical Evaluation of
1101 a New Method for Detecting SARS-CoV-2 Antigen by Fluorescent Microsphere
1102 Immunochromatography. Frontiers in Cellular and Infection Microbiology, 2020; 10:553837.
1103 DOI:10.3389/fcimb.2020.553837.
1104 164. Zou M, Su F, Zhang R, Jiang X, Xiao H, Yan X, et al. Rapid Point-of-Care Testing for SARS-CoV-2
1105 Virus Nucleic Acid Detection by an Isothermal and Nonenzymatic Signal Amplification System
1106 Coupled with a Lateral Flow Immunoassay Strip. Sensors and Actuators B: Chemical, 2021;
1107 342:129899. DOI:10.1016/j.snb.2021.129899.
1108 165. Akingba OL, Sprong K, Hardie DR. Field performance evaluation of the PanBio rapid SARS-
1109 CoV-2 antigen assay in an epidemic driven by 501Y.v2 (lineage B.1.351) in the Eastern Cape, South
1110 Africa. Journal of Clinical Virology Plus, 2021; 1(1-2):100013. DOI:10.1016/j.jcvp.2021.100013.
1111 166. Asai N, Sakanashi D, Ohashi W, Nakamura A, Kawamoto Y, Miyazaki N, et al. Efficacy and
1112 validity of automated quantitative chemiluminescent enzyme immunoassay for SARS-CoV-2 antigen
1113 test from saliva specimen in the diagnosis of COVID-19. Journal of Infection and Chemotherapy,
1114 2021; available online. DOI:10.1016/j.jiac.2021.03.021.
1115 167. Baro B, Rodo P, Ouchi D, Bordoy A, Saya Amaro E, Salsench S, et al. Performance
1116 characteristics of five antigen-detecting rapid diagnostic test (Ag-RDT) for SARS-CoV-2 asymptomatic
1117 infection: a head-to-head benchmark comparison. Journal of Infection, 2021; 82(6):269-275.
1118 DOI:10.1016/j.jinf.2021.04.009.
1119 168. Basso D, Aita A, Padoan A, Cosma C, Navaglia F, Moz S, et al. Salivary SARS-CoV-2 antigen
1120 rapid detection: a prospective cohort study. Clinica Chimica Acta, 2020; 517:54-59.
1121 DOI:10.1016/j.cca.2021.02.014.
1122 169. Bruzzone B, De Pace V, Caligiuri P, Ricucci V, Guarona G, Pennati BM, et al. Comparative
1123 diagnostic performance of different rapid antigen detection tests for COVID-19 in the real-world
1124 hospital setting. International Journal of Infectious Diseases, 2021; 107:215-218.
1125 DOI:10.1016/j.ijid.2021.04.072.
1126 170. Caruana G, Croxatto A, Kampouri E, Kritikos A, Opota O, Foerster M, et al. ImplemeNting
1127 SARS-CoV-2 Rapid antigen testing in the Emergency wArd of a Swiss univErsity hospital: the INCREASE
1128 study. Microorganisms, 2021; 9(4):798. DOI:10.3390/microorganisms9040798.
1129 171. Caruana G, Lebrun L-L, Aebischer O, Opota O, Urbano L, DeRham M, et al. The dark side of
1130 SARS-CoV-2 rapid antigen testing: screening asymptomatic patients. medRxiv [Preprint]; published
1131 April 27, 2021. DOI:10.1101/2021.04.24.21256040.
1132 172. Ciotti M, Maurici M, Pieri M, Andreoni M, Bernardini S. Performance of a rapid antigen test in
1133 the diagnosis of SARS-CoV-2 infection. Journal of Medical Virology, 2021; 93:2988–2991.
1134 DOI:10.1002/jmv.26830.
1135 173. Cubas Atienzar A, Kontogianni K, Edwards T, Wooding D, Buist K, Thompson C, et al. Limit of
1136 detection in different matrices of nineteen commercially available rapid antigen tests for the
1137 detection of SARS-CoV-2. medRxiv [Preprint]; published March 22, 2021.
1138 DOI:10.1101/2021.03.19.21253950.
1139 174. Del Vecchio C, Brancaccio G, Brazzale AR, Lavezzo E, Onelia F, Franchin E, et al. Emergence of
1140 N antigen SARS-CoV-2 genetic variants escaping detection of antigenic tests. medRxiv [Preprint];
1141 published March 26, 2021. DOI:10.1101/2021.03.25.21253802.
1142 175. Domínguez Fernández M, Peña Rodríguez MF, Lamelo Alfonsín F, Bou Arévalo G. Experience
1143 with Panbio™ rapid antigens test device for the detection of SARS-CoV-2 in nursing homes.
1144 Enfermedades Infecciosas y Microbiología Clínica, 2021; S0213-005X.
1145 DOI:10.1016/j.eimc.2020.12.008.
1146 176. Drain PK, Ampajwala M, Chappel C, Gvozden AB, Hoppers M, Wang M, et al. A Rapid, High-
1147 Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point
1148 of Care: A Clinical Performance Study. Infectious Diseases and Therapy, 2021; 10(2):753–761.
1149 DOI:10.1007/s40121-021-00413-x.

1150 177. Faíco-Filho KS, Finamor Júnior FE, Moreira LVL, Lins PRG, Justo AFO, Bellei N. Evaluation of
1151 the Panbio™ COVID-19 Ag Rapid Test at an Emergency Room in a Hospital in São Paulo, Brazil.
1152 medRxiv [Preprint]; published March 24, 2021. DOI:10.1101/2021.03.15.21253313.
1153 178. Favresse J, Gillot C, Oliveira M, Cadrobbi J, Elsen M, Eucher C, et al. Head-to-Head
1154 Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-CoV-2
1155 Infection. Journal of Clinical Medicine, 2021; 10(2):265. DOI:10.3390/jcm10020265.
1156 179. Ferguson J, Dunn S, Best A, Mirza J, Percival B, Mayhew M, et al. Validation testing to
1157 determine the sensitivity of lateral flow testing for asymptomatic SARS-CoV-2 detection in low
1158 prevalence settings: Testing frequency and public health messaging is key. PLoS Biol, 2021;
1159 19(4):e3001216. DOI:10.1371/journal.pbio.3001216.
1160 180. Filgueiras P, Corsini C, Almeida NBF, Assis J, Pedrosa ML, de Oliveira A, et al. COVID-19 Rapid
1161 Antigen Test at hospital admission associated to the knowledge of individual risk factors allow
1162 overcoming the difficulty of managing suspected patients in hospitals COVID-19 Rapid Antigen Test
1163 facilitates the management of suspected patients on hospital admission. medRxiv [Preprint];
1164 published January 08, 2021. DOI:10.1101/2021.01.06.21249282.
1165 181. Foundation for Innovative New Diagnostics. FIND Evaluation of Boditech Medical, Inc.
1166 iChroma COVID-19 Ag Test. External Report Version 10, 23 February 2021, 2021.
1167 182. Foundation for Innovative New Diagnostics. FIND Evaluation of Joysbio (Tianjin)
1168 Biotechnology Co., Ltd. SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold). External Report Version
1169 10, 11 February 2021, 2021.
1170 183. Foundation for Innovative New Diagnostics. FIND Evaluation of Guangzhou Wondfo Biotech
1171 Co., Ltd Wondfo 2019-nCoV Antigen Test (Lateral Flow Method). Public Report Version 10, 25
1172 February 2021, 2021.
1173 184. Foundation for Innovative New Diagnostics. FIND Evaluation of Abbott Panbio COVID-19 Ag
1174 Rapid Test Device (NASAL). External Report Version 10, 11 February 2021, 2021.
1175 185. Foundation for Innovative New Diagnostics. FIND Evaluation of Bionote, Inc. NowCheck
1176 COVID-19 Ag Test, nasal swab. External Report Version 10, 30 March 2021, 2021.
1177 186. Foundation for Innovative New Diagnostics. FIND Evaluation of Fujirebio Inc. Espline SARS-
1178 CoV-2. External Report Version 10, 29 March 2021, 2021.
1179 187. Foundation for Innovative New Diagnostics. FIND Evaluation of Mologic Ltd, COVID 19 RAPID
1180 ANTIGEN TEST. External Report Version 10, 23 April 2021, 2021.
1181 188. Foundation for Innovative New Diagnostics. FIND Evaluation of NADAL COVID-19 Ag Rapid
1182 Test. External Report Version 10, 26 April 2021, 2021.
1183 189. Gili A, Paggi R, Russo C, Cenci E, Pietrella D, Graziani A, et al. Evaluation of automated test
1184 Lumipulse® G SARS-CoV-2 antigen assay for detection of SARS-CoV-2 nucleocapsid protein (NP) in
1185 nasopharyngeal swabs for community and population screening. International Journal of Infectious
1186 Diseases, 2021; 105:P391-396. DOI:10.1016/j.ijid.2021.02.098.
1187 190. Gomez Marti JL, Gribschaw J, McCullough M, Mallon A, Acero J, Kinzler A, et al. Differences in
1188 detected viral loads guide use of SARS-CoV-2 antigen-detection assays towards symptomatic college
1189 students and children. medRxiv [Preprint]; published February 01, 2021.
1190 DOI:10.1101/2021.01.28.21250365.
1191 191. Haage V, Ferreira de Oliveira-Filho E, Moreira-Soto A, Kühne A, Fischer C, Sacks JA, et al.
1192 Impaired performance of SARS-CoV-2 antigen-detecting rapid diagnostic tests at elevated and low
1193 temperatures. Journal of Clinical Virology, 2021; 138:104796. DOI:10.1016/j.jcv.2021.104796.
1194 192. Halfon P, Penaranda G, Khiri H, Garcia V, Drouet H, Philibert P, et al. An optimized stepwise
1195 algorithm combining rapid antigen and RT-qPCR for screening of COVID-19 patients. medRxiv
1196 [Preprint]; published January 15, 2021. DOI:10.1101/2021.01.13.21249254.
1197 193. Hirotsu Y, Maejima M, Shibusawa M, Amemiya K, Nagakubo Y, Hosaka K, et al. Prospective
1198 Study of 1,308 Nasopharyngeal Swabs from 1,033 Patients using the LUMIPULSE SARS-CoV-2 Antigen
1199 Test: Comparison with RT-qPCR. International Journal of Infectious Diseases, 2021; 105:7-14.
1200 DOI:10.1016/j.ijid.2021.02.005.

1201 194. Homza M, Zelena H, Janosek J, Tomaskova H, Jezo E, Kloudova A, et al. Five Antigen Tests for
1202 SARS-CoV-2: Virus Viability Matters. Viruses, 2021; 13(4). DOI:10.3390/v13040684.
1203 195. Houston H, Gupta-Wright A, Toke-Bjolgerud E, Biggin-Lamming J, John L. Diagnostic accuracy
1204 and utility of SARS-CoV-2 antigen lateral flow assays in medical admissions with possible COVID-19.
1205 Journal of Hospital Infection, 2021; 110:203-205. DOI:10.1016/j.jhin.2021.01.018.
1206 196. Jääskeläinen AE, Ahava MJ, Jokela P, Szirovicza L, Pohjala S, Vapalahti O, et al. Evaluation of
1207 three rapid lateral flow antigen detection tests for the diagnosis of SARS-CoV-2 infection. Journal of
1208 Clinical Virology, 2021; 137:104785. DOI:10.1101/2020.12.30.20249057.
1209 197. James AE, Gulley T, Kothari A, Holder K, Garner K, Patil N. Performance of the BinaxNOW
1210 COVID-19 Antigen Card test relative to the SARS-CoV-2 real-time reverse transcriptase polymerase
1211 chain reaction assay among symptomatic and asymptomatic healthcare employees. Infection Control
1212 and Hospital Epidemiology, 2021:1-3. DOI:10.1017/ice.2021.20.
1213 198. Jungnick S, Hobmaier B, Mautner L, Hoyos M, Haase M, Baiker A, et al. Detection of the new
1214 SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in five SARS-CoV-2 rapid antigen tests (RATs),
1215 Germany, March 2021. Euro Surveillance, 2021; 26(16):2100413. DOI:10.2807/1560-
1216 7917.Es.2021.26.16.2100413.
1217 199. Kannian P, Lavanya C, Ravichandran K, Gita JB, Mahanathi P, Ashwini V, et al. SARS-CoV2
1218 antigen in whole mouth fluid may be a reliable rapid detection tool. Oral Diseases, 2021; 00:1-2.
1219 DOI:10.1111/odi.13793.
1220 200. Kenyeres B, Ánosi N, Bányai K, Mátyus M, Orosz L, Kiss A, et al. Comparison of four PCR and
1221 two point of care assays used in the laboratory detection of SARS-CoV-2. Journal of Virological
1222 Methods, 2021; 293:114165. DOI:10.1016/j.jviromet.2021.114165.
1223 201. Kernéis S, Elie C, Fourgeaud J, Choupeaux L, Delarue SM, Alby M-L, et al. Accuracy of antigen
1224 and nucleic acid amplification testing on saliva and naopharyngeal samples for detection of SARS-
1225 CoV-2 in ambulatory care. medRxiv [Preprint]; published April 11, 2021.
1226 DOI:10.1101/2021.04.08.21255144.
1227 202. Kilic A, Hiestand B, Palavecino E. Evaluation of Performance of the BD Veritor SARS-CoV-2
1228 Chromatographic Immunoassay Test in Patients with Symptoms of COVID-19. Journal of Clinical
1229 Microbiology, 2021; 59(5). DOI:10.1128/jcm.00260-21.
1230 203. Kohmer N, Toptan T, Pallas C, Karaca O, Pfeiffer A, Westhaus S, et al. The Comparative
1231 Clinical Performance of Four SARS-CoV-2 Rapid Antigen Tests and Their Correlation to Infectivity In
1232 Vitro. Journal of Clinical Medicine, 2021; 10(2). DOI:10.3390/jcm10020328.
1233 204. Krüger L, Klein JAF, Tobian F, Gaeddert M, Lainati F, Klemm S, et al. Evaluation of accuracy,
1234 exclusivity, limit-of-detection and ease-of-use of LumiraDx™-Antigen-detecting point-of-care device
1235 for SARS-CoV-2. medRxiv [Preprint]; published March 05, 2021. DOI:10.1101/2021.03.02.21252430.
1236 205. L'Huillier A, Lacour M, Sadiku D, Gadiri M, De Siebenthal L, Schibler M, et al. Diagnostic
1237 accuracy of SARS-CoV-2 rapid antigen detection testing in symptomatic and asymptomatic children in
1238 the clinical setting. medRxiv [Preprint]; published April 20, 2021. DOI:10.1101/2021.04.15.21255577.
1239 206. Lefever S, Indevuyst C, Cuypers L, Dewaele K, Yin N, Cotton F, et al. Comparison of the
1240 quantitative DiaSorin Liaison antigen test to RT-PCR for the diagnosis of COVID-19 in symptomatic
1241 and asymptomatic outpatients. Journal of Clinical Microbiology, 2021; Online ahead of print.
1242 DOI:10.1128/jcm.00374-21.
1243 207. Lindner A, Nikolai O, Rohardt C, Kausch F, Wintel M, Gertler M, et al. SARS-CoV-2 patient self-
1244 testing with an antigen-detecting rapid test: a head-to-head comparison with professional testing.
1245 medRxiv [Preprint]; published January 08, 2021. DOI:10.1101/2021.01.06.20249009.
1246 208. Mak GCK, Lau SSY, Wong KKY, Chow NLS, Lau CS, Lam ETK, et al. Evaluation of rapid antigen
1247 detection kit from the WHO Emergency Use List for detecting SARS-CoV-2. Journal of Clinical
1248 Virology, 2021; 134:104712. DOI:10.1016/j.jcv.2020.104712.
1249 209. Mboumba Bouassa RS, Veyer D, Péré H, Bélec L. Analytical performances of the point-of-care
1250 SIENNA™ COVID-19 Antigen Rapid Test for the detection of SARS-CoV-2 nucleocapsid protein in
1251 nasopharyngeal swabs: A prospective evaluation during the COVID-19 second wave in France.
1252 International Journal of Infectious Diseases, 2021; 106:8-12. DOI:10.1016/j.ijid.2021.03.051.

1253 210. Menchinelli G, Bordi L, Marzialiotti F, Palucci I, Capobianchi M, Sberna G, et al. Lumipulse G
1254 SARS-CoV-2 Ag Assay Evaluation for SARS-CoV-2 Antigen Detection Using 594 Nasopharyngeal Swab
1255 Samples from Different Testing Groups. Clinical Chemistry and Laboratory Medicine, 2021; Online
1256 ahead of print. DOI:10.1515/cclm-2021-0182.
1257 211. Micocci M, Buckle P, Hayward G, Allen J, Davies K, Kierkegaard P, et al. Point of Care Testing
1258 using rapid automated Antigen Testing for SARS-COV-2 in Care Homes – an exploratory safety,
1259 usability and diagnostic agreement evaluation. medRxiv [Preprint]; published April 26, 2021.
1260 DOI:10.1101/2021.04.22.21255948.
1261 212. Möckel M, Corman VM, Stegemann MS, Hofmann J, Stein A, Jones TC, et al. SARS-CoV-2
1262 Antigen Rapid Immunoassay for Diagnosis of COVID-19 in the Emergency Department. Biomarkers,
1263 2021; 26(3):213-220. DOI:10.1080/1354750x.2021.1876769.
1264 213. Muhi S, Tayler N, Hoang T, Ballard SA, Graham M, Rojek A, et al. Multi-site assessment of
1265 rapid, point-of-care antigen testing for the diagnosis of SARS-CoV-2 infection in a low-prevalence
1266 setting: A validation and implementation study. Lancet Regional Health Western Pacific, 2021;
1267 9:100115. DOI:10.1016/j.lanwpc.2021.100115.
1268 214. Ngo Nsoga M-T, Kronig I, Perez Rodriguez FJ, Sattonnet-Roche P, Da Silva D, Helbling J, et al.
1269 Diagnostic accuracy of PanbioTM rapid antigen tests on oropharyngeal swabs for detection of SARS-
1270 CoV-2. medRxiv [Preprint]; published February 01, 2021. DOI:10.1101/2021.01.30.21250314.
1271 215. Nikolai O, Rohardt C, Tobian F, Junge A, Corman V, Jones T, et al. Anterior nasal versus nasal
1272 mid-turbinate sampling for a SARS-CoV-2 antigen-detecting rapid test: does localisation or
1273 professional collection matter? medRxiv [Preprint]; published February 16, 2021.
1274 DOI:10.1101/2021.02.09.21251274.
1275 216. Nörz D, Olearo F, Perisic S, Bauer M, Riester E, Schneider T, et al. Multicenter evaluation of a
1276 fully automated high-throughput SARS-CoV-2 antigen immunoassay. medRxiv [Preprint]; published
1277 April 15, 2021. DOI:10.1101/2021.04.09.21255047.
1278 217. Okoye NC, Barker AP, Curtis K, Orlandi RR, Snavely EA, Wright C, et al. Performance
1279 Characteristics of BinaxNOW COVID-19 Antigen Card for Screening Asymptomatic Individuals in a
1280 University Setting. Journal of Clinical Microbiology, 2021; 59(4):e03282-20. DOI:10.1128/jcm.03282-
1281 20.
1282 218. Osmanodja B, Budde K, Zickler D, Naik M, Hofmann J, Gertler M, et al. Diagnostic accuracy of
1283 a novel SARS-CoV-2 antigen-detecting rapid diagnostic test from standardized self-collected anterior
1284 nasal swabs. medRxiv [Preprint]; published April 23, 2021. DOI:10.1101/2021.04.20.21255797.
1285 219. Osterman A, Baldauf HM, Eletreby M, Wettengel JM, Afridi SQ, Fuchs T, et al. Evaluation of
1286 two rapid antigen tests to detect SARS-CoV-2 in a hospital setting. Medical Microbiology and
1287 Immunology, 2021; 210(1):65-72. DOI:10.1007/s00430-020-00698-8.
1288 220. Pena M, Ampuero M, Garces C, Gaggero A, Garcia P, Velasquez MS, et al. Performance of
1289 SARS-CoV-2 rapid antigen test compared with real-time RT-PCR in asymptomatic individuals. medRxiv
1290 [Preprint]; published February 13, 2021. DOI:10.1101/2021.02.12.21251643.
1291 221. Pérez-García F, Romanyk J, Gómez-Herruz P, Arroyo T, Pérez-Tanoira R, Linares M, et al.
1292 Diagnostic performance of CerTest and Panbio antigen rapid diagnostic tests to diagnose SARS-CoV-2
1293 infection. Journal of Clinical Virology, 2021; 137:104781. DOI:10.1016/j.jcv.2021.104781.
1294 222. Peto T, Team UC-LFO. COVID-19: Rapid Antigen detection for SARS-CoV-2 by lateral flow
1295 assay: a national systematic evaluation for mass-testing. medRxiv [Preprint]; published January 26,
1296 2021. DOI:10.1101/2021.01.13.21249563.
1297 223. Pickering S, Batra R, Snell L, Merrick B, Nebbia G, Douthwaite S, et al. Comparative
1298 performance of SARS-CoV-2 lateral flow antigen tests demonstrates their utility for high sensitivity
1299 detection of infectious virus in clinical specimens. medRxiv [Preprint]; published March 02, 2021.
1300 DOI:10.1101/2021.02.27.21252427.
1301 224. Pollock N, Jacobs J, Tran K, Cranston A, Smith S, O'Kane C, et al. Performance and
1302 Implementation Evaluation of the Abbott BinaxNOW Rapid Antigen Test in a High-throughput Drive-
1303 through Community Testing Site in Massachusetts. Journal of Clinical Microbiology, 2021; 59(5).
1304 DOI:10.1101/2021.01.09.21249499.

1305 225. Pollock N, Tran K, Jacobs J, Cranston A, Smith S, O'Kane C, et al. Performance and Operational
1306 Evaluation of the Access Bio CareStart Rapid Antigen Test in a High-throughput Drive-through
1307 Community Testing Site in Massachusetts. medRxiv [Preprint]; published March 09, 2021.
1308 DOI:10.1101/2021.03.07.21253101.
1309 226. Ristić M, Nikolić N, Čabarkapa V, Turkulov V, Petrović V. Validation of the STANDARD Q
1310 COVID-19 antigen test in Vojvodina, Serbia. PLoS One, 2021; 16(2):e0247606.
1311 DOI:10.1371/journal.pone.0247606.
1312 227. Rodgers M, Batra R, Snell L, Daghfal D, Roth R, Huang S, et al. Detection of SARS-CoV-2
1313 variants by Abbott molecular, antigen, and serological tests. medRxiv [Preprint]; published April 26,
1314 2021. DOI:10.1101/2021.04.24.21256045.
1315 228. Rottenstreich A, Zarbiv G, Kabiri D, Porat S, Sompolinsky Y, Reubinoff B, et al. Rapid antigen
1316 detection testing for universal screening for severe acute respiratory syndrome coronavirus 2 in
1317 women admitted for delivery. American Journal of Obstetrics and Gynecology, 2021; 224(5):539-540.
1318 DOI:10.1016/j.ajog.2021.01.002.
1319 229. Salvagno GL, Gianfilippi G, Bragantini D, Henry BM, Lippi G. Clinical assessment of the Roche
1320 SARS-CoV-2 rapid antigen test. Diagnosis, 2021; Ahead of print. DOI:10.1515/dx-2020-0154.
1321 230. Sberna G, Lalle E, Capobianchi MR, Bordi L, Amendola A. Letter of concern re:
1322 "Immunochromatographic test for the detection of SARS-CoV-2 in saliva. J Infect Chemother. 2021
1323 Feb;27(2):384-386. doi: 10.1016/j.jiac.2020.11.016.". Journal of Infection and Chemotherapy, 2021;
1324 Article in press. DOI:10.1016/j.jiac.2021.04.003.
1325 231. Schuit E, Veldhuijzen IK, Venekamp RP, van den Bijllaardt W, Pas SD, Lodder EB, et al.
1326 Diagnostic accuracy of rapid antigen tests in pre-/asymptomatic close contacts of individuals with a
1327 confirmed SARS-CoV-2 infection. medRxiv [Preprint]; published March 23, 2021.
1328 DOI:10.1101/2021.03.18.21253874.
1329 232. Seitz T, Schindler S, Winkelmeyer P, Zach B, Wenisch C, Zoufaly A, et al. Evaluation of rapid
1330 antigen tests based on saliva for the detection of SARS-CoV-2. Journal of Medical Virology, 2021;
1331 Online ahead of print. DOI:10.1002/jmv.26983.
1332 233. Shidlovskaya E, Kuznetsova N, Divisenko E, Nikiforova M, Siniavin A, Ogarkova D, et al. The
1333 Value of Rapid Antigen Tests to Identify Carriers of Viable SARS-CoV-2. medRxiv [Preprint]; published
1334 March 12, 2021. DOI:10.1101/2021.03.10.21252667.
1335 234. Stohr JJM, Zwart VF, Goderski G, Meijer A, Nagel-Imming RS, Kluytmans-van den Bergh MFQ,
1336 et al. Self-testing for the detection of SARS-CoV-2 infection with rapid antigen tests. medRxiv
1337 [Preprint]; published February 23, 2021. DOI:10.1101/2021.02.21.21252153.
1338 235. Stokes W, Berenger BM, Portnoy D, Scott B, Szelewicki J, Singh T, et al. Clinical performance
1339 of the Abbott Panbio with nasopharyngeal, throat, and saliva swabs among symptomatic individuals
1340 with COVID-19. European Journal of Clinical Microbiology & Infectious Diseases, 2021; Online ahead
1341 of print. DOI:10.1007/s10096-021-04202-9.
1342 236. Strömer A, Rose R, Schäfer M, Schön F, Vollersen A, Lorentz T, et al. Performance of a Point-
1343 of-Care Test for the Rapid Detection of SARS-CoV-2 Antigen. Microorganisms, 2020; 9(1).
1344 DOI:10.3390/microorganisms9010058.
1345 237. Takeuchi Y, Akashi Y, Kato D, Kuwahara M, Muramatsu S, Ueda A, et al. The evaluation of a
1346 newly developed antigen test (QuickNavi™-COVID19 Ag) for SARS-CoV-2: A prospective observational
1347 study in Japan. Journal of Infection and Chemotherapy, 2021; 27(6):890-894.
1348 DOI:10.1016/j.jiac.2021.02.029.
1349 238. Takeuchi Y, Akashi Y, Kato D, Kuwahara M, Muramatsu S, Ueda A, et al. Diagnostic
1350 Performance and Characteristics of Anterior Nasal Collection for the SARS-CoV-2 Antigen Test: A
1351 Prospective Study in Japan. medRxiv [Preprint]; published March 05, 2021. DOI:10.1038/s41598-021-
1352 90026-8.
1353 239. Thakur P, Saxena S, Manchanda V, Rana N, Goel R, Arora R. Utility of Antigen-Based Rapid
1354 Diagnostic Test for Detection of SARS-CoV-2 Virus in Routine Hospital Settings. Lab Med, 2021;
1355 Online ahead of print. DOI:10.1093/labmed/lmab033.

1356 240. Thell R, Kallab V, Weinhappel W, Mueckstein W, Heschl L, Heschl M, et al. Evaluation of a
1357 novel, rapid antigen detection test for the diagnosis of SARS-CoV-2. medRxiv [Preprint]; published
1358 April 22, 2021. DOI:10.1101/2021.04.22.21255637.
1359 241. Torres I, Poujois S, Albert E, Álvarez G, Colomina J, Navarro D. Point-of-care evaluation of a
1360 rapid antigen test (CLINITEST(®) Rapid COVID-19 Antigen Test) for diagnosis of SARS-CoV-2 infection
1361 in symptomatic and asymptomatic individuals. Journal of Infection, 2021; 82(5):e11–e12.
1362 DOI:10.1016/j.jinf.2021.02.010.
1363 242. Turcato G, Zaboli A, Pfeifer N, Ciccariello L, Sibilio S, Tezza G, et al. Clinical application of a
1364 rapid antigen test for the detection of SARS-CoV-2 infection in symptomatic and asymptomatic
1365 patients evaluated in the emergency department: a preliminary report. Journal of Infection, 2020;
1366 82:E14-E16. DOI:10.1016/j.jinf.2020.12.012.
1367 243. Villaverde S, Domínguez-Rodríguez S, Sabrido G, Pérez-Jorge C, Plata M, Romero MP, et al.
1368 Diagnostic Accuracy of the Panbio SARS-CoV-2 Antigen Rapid Test Compared with Rt-Pcr Testing of
1369 Nasopharyngeal Samples in the Pediatric Population. The Journal of Pediatrics, 2021; 232:P287-
1370 289.E4. DOI:10.1016/j.jpeds.2021.01.027.
1371 244. Wagenhäuser I, Knies K, Rauschenberger V, Eisenmann M, McDonogh M, Petri N, et al.
1372 Clinical performance evaluation of SARS-CoV-2 rapid antigen testing in point of care usage in
1373 comparison to RT-qPCR. medRxiv [Preprint]; published March 29, 2021.
1374 DOI:10.1101/2021.03.27.21253966.
1375 245. Yin N, Debuysschere C, Decroly M, Bouazza FZ, Collot V, Martin C, et al. SARS-CoV-2
1376 Diagnostic Tests: Algorithm and Field Evaluation From the Near Patient Testing to the Automated
1377 Diagnostic Platform. Frontiers in Medicine, 2021; 8:380. DOI:10.3389/fmed.2021.650581.
1378 246. Young BC, Eyre DW, Jeffery K. Use of lateral flow devices allows rapid triage of patients with
1379 SARS-CoV-2 on admission to hospital. Journal of Infection, 2021; 82:276-316.
1380 DOI:10.1016/j.jinf.2021.02.025.
1381 247. Abdulrahman A, Mustafa F, AlAwadhi AI, Alansari Q, AlAlawi B, AlQahtani M. Comparison of
1382 SARS-COV-2 nasal antigen test to nasopharyngeal RT-PCR in mildly symptomatic patients. medRxiv
1383 [Preprint]; published December 08, 2020. DOI:10.1101/2020.11.10.20228973.
1384 248. Agulló V, Fernández-González M, Ortiz de la Tabla V, Gonzalo-Jiménez N, García JA, Masiá M,
1385 et al. Evaluation of the rapid antigen test Panbio COVID-19 in saliva and nasal swabs: A population-
1386 based point-of-care study. Journal of Infection, 2020; published online ahead of issue.
1387 DOI:10.1016/j.jinf.2020.12.007.
1388 249. Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernandez-Fuentes MA, et al. Field evaluation
1389 of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary
1390 healthcare centres. Clinical Microbiology and Infection, 2020; 27(3):472.e7–472.e10.
1391 DOI:10.1016/j.cmi.2020.11.004.
1392 250. Alemany A, Baro B, Ouchi D, Ubals M, Corbacho-Monné M, Vergara-Alert J, et al. Analytical
1393 and Clinical Performance of the Panbio COVID-19 Antigen-Detecting Rapid Diagnostic Test. Journal of
1394 Infection, 2020; 82(5):186-230. DOI:10.1016/j.jinf.2020.12.033.
1395 251. Beck ET, Paar W, Fojut L, Serwe J, Jahnke RR. Comparison of Quidel Sofia SARS FIA Test to
1396 Hologic Aptima SARS-CoV-2 TMA Test for Diagnosis of COVID-19 in Symptomatic Outpatients. Journal
1397 of Clinical Microbiology, 2020; 59(2):e02727-20. DOI:10.1128/jcm.02727-20.
1398 252. Berger A, Ngo Nsoga M-T, Perez Rodriguez FJ, Abi Aad Y, Sattonnet P, Gayet-Ageron A, et al.
1399 Diagnostic accuracy of two commercial SARS-CoV-2 Antigen-detecting rapid tests at the point of care
1400 in community-based testing centers. PLoS One, 2020; 16(3):e0248921.
1401 DOI:10.1371/journal.pone.0248921.
1402 253. Bulilete O, Lorente P, Leiva A, Carandell E, Oliver A, Rojo E, et al. Evaluation of the Panbio™
1403 rapid antigen test for SARS-CoV-2 in primary health care centers and test sites. medRxiv [Preprint];
1404 published November 16, 2020. DOI:10.1101/2020.11.13.20231316.
1405 254. Cerutti F, Burdino E, Milia MG, Allice T, Gregori G, Bruzzone B, et al. Urgent need of rapid
1406 tests for SARS CoV-2 antigen detection: Evaluation of the SD-Biosensor antigen test for SARS-CoV-2.
1407 Journal of Clinical Virology, 2020; 132:104654. DOI:10.1016/j.jcv.2020.104654.

255. Chaimayo C, Kaewnaphan B, Tanlieng N, Athipanyasilp N, Sirijatuphat R, Chayakulkeeree M, et al. Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand. Virology Journal, 2020; 17(1):177. DOI:10.1186/s12985-020-01452-5.

256. Corman V, Haage V, Bleicker T, Schmidt ML, Muehlemann B, Zuchowski M, et al. Comparison of seven commercial SARS-CoV-2 rapid Point-of-Care Antigen tests. The Lancet Microbe, 2020; Online First. DOI:10.1016/S2666-5247(21)00056-2.

257. Drevinek P, Hurych J, Kepka Z, Briksi A, Kulich M, Zajac M, et al. The sensitivity of SARS-CoV-2 antigen tests in the view of large-scale testing. medRxiv [Preprint]; published November 24, 2020. DOI:10.1101/2020.11.23.20237198.

258. Fenollar F, Bouam A, Ballouche M, Fuster L, Prudent E, Colson P, et al. Evaluation of the Panbio Covid-19 rapid antigen detection test device for the screening of patients with Covid-19. Journal of Clinical Microbiology, 2020; 59:e02589-20. DOI:10.1128/JCM.02589-20.

259. Foundation for Innovative New Diagnostics. FIND Evaluation of Bionote, Inc. NowCheck COVID-19 Ag Test. External Report Version 15, 20 April 2021, 2020.

260. Foundation for Innovative New Diagnostics. FIND Evaluation of RapiGEN Inc. BIOCREDIT COVID-19 Ag. External Report Version 21, 10 December, 2020.

261. Foundation for Innovative New Diagnostics. FIND Evaluation of SD Biosensor, Inc. STANDARD™ F COVID-19 Ag FIA. External Report Version 21, 10 December, 2020.

262. Foundation for Innovative New Diagnostics. FIND Evaluation of SD Biosensor, Inc. STANDARD Q COVID-19 Ag Test. External Report Version 21, 10 December, 2020.

263. Gremmels H, Winkela BMF, Schuurmana R, Rosinghb A, Rigterc NAM, Rodriguezd O, et al. Real-life validation of the Panbio COVID-19 Antigen Rapid Test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection. EClinicalMedicine, 2020; 31:100677. DOI:10.1016/j.eclinm.2020.100677.

264. Gupta A, Khurana S, Das R, Srigyan D, Singh A, Mittal A, et al. Rapid chromatographic immunoassay-based evaluation of COVID-19: A cross-sectional, diagnostic test accuracy study & its implications for COVID-19 management in India. Indian Journal of Medical Research, 2020; 153(1):126. DOI:10.4103/ijmr.IJMR_3305_20.

265. Herrera V, Hsu V, Adewale A, Hendrix T, Johnson L, Kuhlman J, et al. Testing of Healthcare Workers Exposed to COVID19 with Rapid Antigen Detection. medRxiv [Preprint]; published August 18, 2020. DOI:10.1101/2020.08.12.20172726.

266. Igl⍰i Z, Velzing J, van Beek J, van de Vijver D, Aron G, Ensing R, et al. Clinical evaluation of the Roche/SD Biosensor rapid antigen test with symptomatic, non-hospitalized patients in a municipal health service drive-through testing site. Emerging Infectious Diseases, 2020; 27(5):1323-1329. DOI:10.3201/eid2705.204688.

267. Krüger LJ, Gaeddert M, Tobian F, Lainati F, Gottschalk C, Klein JAF, et al. Evaluation of the accuracy and ease-of-use of Abbott PanBio - A WHO emergency use listed, rapid, antigen-detecting point-of-care diagnostic test for SARS-CoV-2. medRxiv [Preprint]; published December 07, 2020. DOI:10.1101/2020.11.27.20239699.

268. Krüttgen A, Cornelissen CG, Dreher M, Hornef MW, Imöhl M, Kleinesa M. Comparison of the SARS-CoV-2 Rapid antigen test to the real star Sars-CoV-2 RT PCR kit. Journal of Virological Methods, 2020; 288:114024. DOI:10.1016/j.jviromet.2020.114024.

269. Lambert-Niclot S, Cuffel A, Le Pape S, Vauloup-Fellous C, Morand-Joubert L, Roque-Afonso AM, et al. Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs. Journal of Clinical Microbiology, 2020; 58(8):e00977-20. DOI:10.1128/jcm.00977-20.

270. Linares M, Pérez-Tanoira R, Carrero A, Romanyk J, Pérez-García F, Gómez-Herruz P, et al. Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms. Journal of Clinical Virology, 2020; 133:104659. DOI:10.1016/j.jcv.2020.104659.

1458 271. Lindner A, Nikolai O, Rohardt C, Burock S, Hülso C, Bölke A, et al. Head-to-head comparison of
1459 SARS-CoV-2 antigen-detecting rapid test with professional-collected nasal versus nasopharyngeal
1460 swab. European Respiratory Journal, 2020; in press. DOI:10.1183/13993003.04430-2020.
1461 272. Lindner AK, Nikolai O, Kausch F, Wintel M, Hommes F, Gertler M, et al. Head-to-head
1462 comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swab versus
1463 professional-collected nasopharyngeal swab. European Respiratory Journal, 2021; 57(4).
1464 DOI:10.1183/13993003.03961-2020.
1465 273. Liotti FM, Menchinelli G, Lalle E, Palucci I, Marchetti S, Colavita F, et al. Performance of a
1466 novel diagnostic assay for rapid SARS-CoV-2 antigen detection in nasopharynx samples. Clinical
1467 Microbiology and Infection, 2020; 27:487–488. DOI:10.1016/j.cmi.2020.09.030.
1468 274. Mak GC, Lau SS, Wong KK, Chow NL, Lau CS, Lam ET, et al. Analytical sensitivity and clinical
1469 sensitivity of the three rapid antigen detection kits for detection of SARS-CoV-2 virus. Journal of
1470 Clinical Virology, 2020; 133:104684. DOI:10.1016/j.jcv.2020.104684.
1471 275. Mak GCK, Cheng PKC, Lau SSY, Wong KKY, Lau CS, Lam ETK, et al. Evaluation of rapid antigen
1472 test for detection of SARS-CoV-2 virus. Journal of Clinical Virology, 2020; 129:104500.
1473 DOI:10.1016/j.jcv.2020.104500.
1474 276. Merino-Amador P, Guinea J, Muñoz-Gallego I, González-Donapetry P, Galán J-C, Antona N, et
1475 al. Multicenter evaluation of the Panbio™ COVID-19 Rapid Antigen-Detection Test for the diagnosis of
1476 SARS-CoV-2 infection. Clinical Microbiology and Infection, 2020; 27(5):758-761.
1477 DOI:10.1016/j.cmi.2021.02.001.
1478 277. Mertens P, De Vos N, Martiny D, Jassoy C, Mirazimi A, Cuypers L, et al. Development and
1479 Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context.
1480 Frontiers in Medicine, 2020; 7:225. DOI:10.3389/fmed.2020.00225.
1481 278. Nalumansi A, Lutalo T, Kayiwa J, Watera C, Balinandi S, Kiconco J, et al. Field Evaluation of the
1482 Performance of a SARS-CoV-2 Antigen Rapid Diagnostic Test in Uganda using Nasopharyngeal
1483 Samples. International Journal of Infectious Diseases, 2020; article in press.
1484 DOI:10.1016/j.ijid.2020.10.073.
1485 279. Olearo F, Nörz D, Heinrich F, Sutter JP, Rödel K, Schultze A, et al. Handling and accuracy of
1486 four rapid antigen tests for the diagnosis of SARS-CoV-2 compared to RT-qPCR. Journal of Clinical
1487 Virology, 2020; 137:104782. DOI:10.1016/j.jcv.2021.104782.
1488 280. Parada-Ricart E, Gomez-Bertomeu F, Picó-Plana E, Olona-Cabases M. Usefulness of the
1489 antigen for diagnosing SARS-CoV-2 infection in patients with and without symptoms. Enfermedades
1490 Infecciosas y Microbiología Clínica, 2020; S2529-993X. DOI:10.1016/j.eimc.2020.09.009.
1491 281. Pekosz A, Cooper C, Parvu V, Li M, Andrews J, Manabe YCC, et al. Antigen-based testing but
1492 not real-time PCR correlates with SARS-CoV-2 virus culture. Clinical Infectious Diseases, 2020;
1493 ciaa1706. DOI:10.1093/cid/ciaa1706.
1494 282. Perchetti GA, Huang ML, Mills MG, Jerome KR, Greninger AL. Analytical Sensitivity of the
1495 Abbott BinaxNOW COVID-19 Ag CARD. Journal of Clinical Microbiology, 2020; accepted manuscript
1496 posted online. DOI:10.1128/jcm.02880-20.
1497 283. Pilarowski G, Lebel P, Sunshine S, Liu J, Crawford E, Marquez C, et al. Performance
1498 characteristics of a rapid SARS-CoV-2 antigen detection assay at a public plaza testing site in San
1499 Francisco. The Journal of Infectious Diseases, 2020; 223(7):1139-1144.
1500 DOI:10.1101/2020.11.02.20223891.
1501 284. Porte L, Legarraga P, Iruretagoyena M, Vollrath V, Pizarro G, Munita J, et al. Rapid SARS-CoV-
1502 2 antigen detection by immunofluorescence – a new tool to detect infectivity. medRxiv [Preprint];
1503 published October 06, 2020. DOI:10.1101/2020.10.04.20206466.
1504 285. Porte L, Legarraga P, Vollrath V, Aguilera X, Munita JM, Araos R, et al. Evaluation of a novel
1505 antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples.
1506 International Journal of Infectious Diseases, 2020; 99:328-333. DOI:10.1016/j.ijid.2020.05.098.
1507 286. Schildgen V, Demuth S, Lüsebrink J, Schildgen O. Limits and opportunities of SARS-CoV-2
1508 antigen rapid tests – an experience based perspective. Pathogens, 2020; 10(38).
1509 DOI:10.3390/pathogens10010038.

1510 287. Schwob J-M, Miauton A, Petrovic D, Perdrix J, Senn N, Jaton K, et al. Antigen rapid tests,
1511 nasopharyngeal PCR and saliva PCR to detect SARS-CoV-2: a prospective comparative clinical trial.
1512 medRxiv [Preprint]; published November 24, 2020. DOI:10.1101/2020.11.23.20237057.
1513 288. Scohy A, Anantharajah A, Bodeus M, Kabamba-Mukadi B, Verroken A, Rodriguez-Villalobos H.
1514 Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis. Journal
1515 of Clinical Virology, 2020; 129:104455. DOI:10.1016/j.jcv.2020.104455.
1516 289. Shrestha B, Neupane A, Pant S, Shrestha A, Bastola A, Rajbhandari B, et al. Sensitivity and
1517 specificity of lateral flow antigen test kits for covid-19 in asymptomatic population of quarantine
1518 centre of province 3. Kathmandu University Medical Journal, 2020; 18(2):36-39.
1519 290. Takeda Y, Mori M, Omi K. SARS-CoV-2 qRT-PCR Ct value distribution in Japan and possible
1520 utility of rapid antigen testing kit. medRxiv [Preprint]; published June 19, 2020.
1521 DOI:10.1101/2020.06.16.20131243.
1522 291. Toptan T, Eckermann L, Pfeiffer A, Hoehl S, Ciesek S, Drosten C, et al. Evaluation of a SARS-
1523 CoV-2 rapid antigen test: potential to help reduce community spread? Journal of Clinical Virology,
1524 2020; 135:104713. DOI:10.1016/j.jcv.2020.104713.
1525 292. Torres I, Poujois S, Albert E, Colomina J, Navarro D. Real-life evaluation of a rapid antigen test
1526 (Panbio COVID-19 Ag Rapid Test Device) for SARS-CoV-2 detection in asymptomatic close contacts of
1527 COVID-19 patients. Clinical Microbiology and Infection, 2020; 27(4):636.E1-636.E4.
1528 DOI:10.1016/j.cmi.2020.12.022.
1529 293. Van der Moeren N, Zwart V, Lodder E, Van den Bijllaardt W, Van Esch H, Stohr J, et al.
1530 Performance evaluation of a SARS-CoV-2 rapid antigentest: test performance in the community in
1531 the Netherlands. medRxiv [Preprint]; published October 21, 2020.
1532 DOI:10.1101/2020.10.19.20215202.
1533 294. Veyrenche N, Bollore K, Pisoni A, Bedin AS, Mondain AM, Ducos J, et al. Diagnosis value of
1534 SARS-CoV-2 antigen/antibody combined testing using rapid diagnostic tests at hospital admission.
1535 Journal of Medical Virology, 2020; 39(5):3069-3076. DOI:10.1002/jmv.26855.
1536 295. Weitzel T, Legarraga P, Iruretagoyena M, Pizarro G, Vollrath V, Araos R, et al. Comparative
1537 evaluation of four rapid SARS-CoV-2 antigen detection tests using universal transport medium. Travel
1538 Medicine and Infectious Disease, 2020; 39:101942. DOI:10.1016/j.tmaid.2020.101942.
1539 296. Young S, Taylor SN, Cammarata CL, Varnado KG, Roger-Dalbert C, Montano A, et al. Clinical
1540 evaluation of BD Veritor SARS-CoV-2 point-of-care test performance compared to PCR-based testing
1541 and versus the Sofia 2 SARS Antigen point-of-care test. Journal of Clinical Microbiology, 2020; 59(1).
1542 DOI:10.1128/jcm.02338-20.
1543 297. Kissler SM, Fauver JR, Mack C, Olesen SW, Tai C, Shiue KY, et al. SARS-CoV-2 viral dynamics in
1544 acute infections. medRxiv [Preprint]; published December 02, 2020.
1545 DOI:10.1101/2020.10.21.20217042.
1546 298. Lee S, Kim T, Lee E, Lee C, Kim H, Rhee H, et al. Clinical Course and Molecular Viral Shedding
1547 Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community
1548 Treatment Center in the Republic of Korea. JAMA Internal Medicine, 2020; 180(11):1447-1452.
1549 DOI:10.1001/jamainternmed.2020.3862.
1550 299. Kociolek LK, Muller WJ, Yee R, Dien Bard J, Brown CA, Revell PA, et al. Comparison of Upper
1551 Respiratory Viral Load Distributions in Asymptomatic and Symptomatic Children Diagnosed with
1552 SARS-CoV-2 Infection in Pediatric Hospital Testing Programs. Journal of Clinical Microbiology, 2020;
1553 59(1). DOI:10.1128/JCM.02593-20.
1554 300. Turner F, Vandenberg A, Slepnev VI, Car S, Starritt RE, Seger MV, et al. Post-Disease
1555 Divergence in SARS-CoV-2 RNA Detection between Nasopharyngeal, Anterior Nares and Saliva/Oral
1556 Fluid Specimens - Significant Implications for Policy & Public Health. medRxiv [Preprint]; published
1557 January 26, 2021. DOI:10.1101/2021.01.26.21250523.
1558 301. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an
1559 updated list of essential items for reporting diagnostic accuracy studies. British Medical Journal,
1560 2015; 351:h5527. DOI:10.1136/bmj.h5527.

1561 302. Paul-Ehrlich-Institute. Comparative evaluation of the sensitivities of SARSCoV-2 antigen rapid
1562 tests Langen: Federal Institute for Vaccines and Biomedicines; 2020.

1563

1564 *Table 1:* Clinical accuracy data for Ag-RDTs against SARS-CoV-2

Author	Study location	Sample type	Sample condition	IFU conform	Sample size	Sensitivity	Specificity
AAZ, COVID-VIRO® (LFA)							
[287] Schwob, a35.3	Switzerland	NP	fresh	yes	324	84.1% (95% CI 76.9-89.7)	100% (95% CI 98.0*-100*)
Abbott, BinaxNOW™ (LFA)							
[224] Pollock, f17.1	USA	AN	fresh	yes	2308	77.4% (95% CI 72.2-82.1)	99.4% (95% CI 99.0-99.7)
[283] Pilarowski, a29.1	USA	AN/MT	fresh	yes	878	57.7% (95% CI 36.9*-76.6*)	100%* (95% CI 99.6*-100*)
[197] James, f23.1	USA	AN	fresh	yes	2339	56.6% (95% CI 48.3*-64.6*)	99.9% (95% CI 99.6*-100)
[217] Okoye, f51.1	USA	MT	fresh	yes	2645	53.3% (95% CI 37.9*-68.3*)	100% (95% CI 99.9-100)
Abbott, Panbio™ (LFA)							
[175] Domínguez Fernández, f49.1	Spain	unclear	fresh	unclear	30	95.0% (95% CI 75.1*-99.9*)	100% (95% CI 69.2*-100*)
[250] Alemany, a02.1	Spain	NP	banked	no	919	93.4% (95% CI 91.5-95.0)	100% (95% CI 95.8-100)
[184] FINDdx, f42.2	Germany	NP	fresh	yes	281	90.9% (95% CI 78.3*-97.5*)	99.2% (95% CI 97.0-99.9*)
[276] Merino-Amador, a25.1	Spain	NP	fresh	yes	958	90.5% (95% CI 87.0*-93.4*)	98.8% (95% CI 97.6*-99.5*)
[267] Krüger, a52.1	Germany	NP	fresh	yes	1034	87.5% (95% CI 79.6*-93.2*)	99.9% (95% CI 99.4-100)
[287] Schwob, a35.2	Switzerland	NP	fresh	yes	271	86.1% (95% CI 78.6-91.7)	100% (95% CI 97.6*-100*)
[235] Stokes, f65.1	Canada	NP	fresh	yes	1641	86.2%* (95% CI 81.5*-90.1*)	99.9% (95% CI 99.5-100)
[252] Berger, a05.1	Switzerland	NP	fresh	yes	535	85.5% (95% CI 78.0-91.2)	100% (95% CI 99.1-100)
[177] Faíco-Filho, f63.1	Brazil	NP	fresh	yes	127	84.3% (95% CI 73.6*-91.9*)	98.2%* (95% CI 90.6*-100*)
[196] Jääskeläinen, f50.3	Finland	NP	banked	no	190	82.9%* (95% CI 76.0*-88.5*)	100% (95% CI 90.7*-100*)
[247] Abdulrahman, a01.1	Bahrain	AN/MT	fresh	no	4183	82.1% (95% CI 79.2-84.8)	99.1% (95% CI 98.8-99.4)
[263] Gremmels, a12.2	Netherlands	NP	fresh	yes	208	81.0% (95% CI 69.1*-89.8*)	100% (95% CI 97.5-100)
[214] Ngo Nsoga, f28.1	Switzerland	OP	fresh	no	402	81.0% (95% CI 74.2-86.6)	99.1% (95% CI 96.9-99.9)
[245] Yin, f82.2	Belgium	NP	fresh	yes	101	80.8% (95% CI 68.1-89.2)	not provided
[249] Albert, a03.1	Spain	NP	fresh	yes	412	79.6% (95% CI 66.5*-89.4*)	100% (95% CI 99.0-100)
[250] Alemany, a02.2	Spain	AN/MT	banked	no	487	79.5% (95% CI 71.0-86.4)	98.6%* (95% CI 96.9-99.6)
[258] Fenollar, a11.1	France	NP	fresh	yes	341	75.5% (95% CI 69.0*-81.2*)	94.9% (95% CI 89.8*-97.9*)
[270] Linares, a20.1	Spain	NP	fresh	unclear	255	73.3% (95% CI 60.3*-83.9*)	100% (95% CI 98.1*-100*)
[263] Gremmels, a12.1	Netherlands	NP	fresh	yes	1367	72.7*% (95% CI 64.5-79.9)	100% (95% CI 99.7-100)
[192] Halfon, f18.1	France	NP	unclear	no	200	72.0% (95% CI 62.1*-80.5*)	99.0% (95% CI 94.6*-100)
[253] Bulilete, a07.1	Spain	NP	fresh	yes	1362*	71.4% (95% CI 63.2*-78.7)	99.8% (95% CI 99.4-99.9)
[165] Akingba, f30.1	Southafrica	NP	fresh	unclear	657*	69.7%* (95% CI 61.5*-77.0*)	99.4%* (95% CI 98.3*-99.9*)

[174] Del Vecchio, f66.1	Italy	unclear	fresh	unclear	1441	68.9% (95% CI 55.7-80.1)	99.9% (95% CI 99.6-100)
[178] Favresse, f31.2	Belgium	NP	fresh	no	188	67.7% (95% CI 57.4-76.9)	100% (95% CI 96.1-100)
[257] Drevinek, a10.1	Czech Republic	NP	fresh	yes	591	66.4% (95% CI 59.8*-72.5*)	100% (95% CI 99.0-100)
[205] L'Huillier, f72.1	Switzerland	NP	fresh	yes	822	65.5%* (95% CI 56.3*-74.0)	99.9%* (95% CI 99.2*-100)
[221] Pérez-García, f52.2	Spain	NP	banked	no	320	60.0% (95% CI 52.2-67.4)	100% (95% CI 97.6-100)
[248] Agullo, a56.1	Spain	NP	fresh	yes	652*	57.6%* (95% CI 48.7*-66.1*)	99.8% (95% CI 98.9*-100)
[267] Krüger, a52.2	Germany	OP	fresh	no	74	50.0% (95% CI 1.3-98.7)	100% (95% CI 94.9-100)
[286] Schildgen, a33.2	Germany	BAL/TW	unclear	no	73	50.0% (95% CI 34.2*-65.8*)	77.4% (95% CI 58.9*-90.4*)
[292] Torres, a37.1	Spain	NP	fresh	yes	634	48.1% (95% CI 36.7*-59.6*)	100% (95% CI 99.3-100)
[244] Wagenhäuser, f89.2	Germany	OP	fresh	no	1029	46.7% (95% CI 24.8-69.9)	99.6% (95% CI 99.0-99.9)
[243] Villaverde, f55.1	Spain	NP	fresh	yes	1620	45.4% (95% CI 34.1-57.2)	99.8% (95% CI 99.4-99.9)
[248] Agullo, a56.2	Spain	AN/MT	fresh	no	659	44.7% (95% CI 36.1-53.6)	100% (95% CI 99.3*-100)
[279] Olearo, a54.2	Germany	OP	unclear	no	184	44.0%* (95% CI 33.2*-55.3*)	100% (95% CI 96.4*-100)
[170] Caruana, f34.2	Switzerland	NP	fresh	no	532	41.2% (95% CI 32.1*-50.8*)	99.5% (95% CI 98.3*-99.9*)
[167] Baro, f33.1	Spain	NP	banked	no	286	38.6% (95% CI 29.1-48.8)	99.5% (95% CI 97.0-100)
[248] Agullo, a56.3	Spain	saliva	fresh	no	610	23.1% (95% CI 16.0*-31.7*)	100% (95% CI 99.2*-100)
[213] Muhi, f90.1	Australia	NP	fresh	yes	2413	not provided	100% (95% CI 99.7-100)
Abbott, Panbio™ (nasal sampling) (LFA)							
[184] FINDdx, f42.1	Germany	AN/MT	fresh	yes	281	86.4% (95% CI 72.6*-94.8*)	99.2% (95% CI 97.0-99.9*)
Access Bio, CareStart™ COVID-19 Antigen Test (LFA)							
[225] Pollock, f59.1	USA	AN	fresh	yes	1498	57.7% (95% CI 51.1-64.1)	98.3% (95% CI 97.5-99.0)
Assure Tech, Ecotest COVID-19 Antigen Rapid Test (LFA)							
[194] Homza, f87.1	Czech Republic	NP	fresh	yes	318	75.7% (95% CI 66.5-83.5)	96.7% (95% CI 93.3-98.7)
Becton, Dickinson and Company, BD Veritor™ (requires reader)							
[281] Pekosz, a28.1	USA	NP	fresh	no	251	96.4% (95% CI 81.7*-99.9*)	98.7% (95% CI 96.1-99.7)
[293] Van der Moeren, a39.1	Netherlands	MT/OP	banked	no	351*	94.1% (95% CI 71.1-100)	100% (95% CI 98.9-100)
[190] Marti, f46.2	USA	AN	fresh	unclear	unknown	93.8% (95% CI 79.2*-99.2*)	not provided
[245] Yin, f82.1	Belgium	NP	fresh	yes	177	87.7% (95% CI 80.0-92.7)	not provided
[296] Young, a43.1	USA	NP	banked	no	251	76.3%* (95% CI 59.8*-88.6*)	99.5%* (95% CI 97.4*-99.9*)
[202] Kilic, f71.1	USA	AN	fresh	yes	1384	66.4% (95% CI 57.0-74.9)	98.8% (95% CI 98.1-99.3)
[231] Schuit, f64.1	Netherlands	NP	fresh	no	2678	63.9% (95% CI 57.4-70.1)	99.6% (95% CI 99.3-99.8)
[170] Caruana, f34.4	Switzerland	NP	fresh	no	532	41.2% (95% CI 32.1*-50.8*)	99.8%* (95% CI 98.7*-100*)
Becton, Dickinson and Company, Hometest (LFA)							

[234] Stohr, f45.1	Netherlands	AN	fresh	unclear	1604	48.9% (95% CI 41.3*-56.5*)	99.9% (95% CI 99.5-100)
Beijing Savant Biotechnology, SARS-CoV-2 detection kit (LFA)							
[295] Weitzel, a41.3	Chile	NP/OP	banked	no	109	16.7% (95% CI 9.2*-26.8*)	100% (95% CI 88.8*-100)
Biotime, COVID-19 Antigen Test Cassette (LFA)							
[232] Seitz, f68.1	Austria	saliva	fresh	yes	40	44.4% (95% CI 21.5*-69.2*)	100% (95% CI 84.6*-100*)
Bionote, NowCheck® (LFA)							
[185] FINDdx, f91.1	Brazil	AN	fresh	yes	218	89.9% (95% CI 81.0*-95.5*)	98.6% (95% CI 94.9-99.8*)
[185] FINDdx, f91.2	Brazil	NP	fresh	yes	218	89.9% (95% CI 81.0*-95.5*)	98.6% (95% CI 94.9-99.8*)
[259] FINDdx, a61.1	Brazil	NP	fresh	yes	400	89.2% (95% CI 81.5*-94.5*)	97.3% (95% CI 94.8-98.8*)
[228] Rottenstreich, f53.1	Israel	NP	unclear	unclear	1326	55.6% (95% CI 21.2-86.3)	100% (95% CI 99.7-100)
Biotical Health, SARS-CoV-2 Ag Card (LFA)							
[178] Favresse, f31.1	Belgium	NP	fresh	no	188	66.7% (95% CI 56.3-76.0)	98.9% (95% CI 94.1-99.9)
CerTest Biotec, SARS-CoV-2 one step test card (LFA)							
[221] Pérez-García, f52.1	Spain	NP	banked	no	320	53.5% (95% CI 45.7-61.2)	100% (95% CI 97.6-100)
Coris BioConcept, COVID-19 Ag Respi-Strip (LFA)							
[245] Yin, f82.3	Belgium	NP	fresh	yes	135	80.0% (95% CI 69.2-87.7)	not provided
[277] Mertens, a48.1	Belgium	NP	banked	no	328	57.6% (95% CI 48.7*-66.1*)	99.5% (95% CI 97.2*-100*)
[269] Lambert-Niclot, a18.1	France	NP	fresh	no	138	50.0% (95% CI 39.5-60.5)	100% (95% CI 92.0*-100)
[4] Krüger, a17.3	Germany/England	NP/OP	unclear	no	417	50.0% (95% CI 21.5*-78.5)	95.8% (95% CI 93.4-97.4)
[172] Ciotti, f24.1	Italy	NP	fresh	unclear	50	30.8% (95% CI 17.0-47.6)	100% (95% CI 71.5-100)
[288] Scohy, a34.1	Belgium	NP	fresh	no	148	30.2% (95% CI 21.7-39.9)	100% (95% CI 91.6*-100*)
[294] Veyrenche, a40.1	France	NP	fresh	no	65	28.9%* (95% CI 16.4*-44.3*)	100% (95% CI 83.2-100)
Denka, Quick Navi (LFA)							
[237] Takeuchi, f12.1	Japan	NP	fresh	unclear	1186	86.7% (95% CI 78.6-92.5)	100% (95% CI 99.7-100)
[238] Takeuchi, f60.1	Japan	AN	fresh	unclear	862	72.5% (95% CI 58.3-84.1)	100% (95% CI 99.5*-100)
DiaSorin, LIAISON® SARS-CoV-2 Ag (LFA)							
[206] Lefever, f70.1	Belgium	NP	banked	no	414	67.6%* (95% CI 60.8*-74.0*)	100% (95% CI 98.3*-100)
Dräger, Antigen Test SARS-CoV-2 (LFA)							
[218] Osmanodja, f79.1	Germany	NP/OP	fresh	yes	379	88.6% (95% CI 78.7-94.9)	99.7% (95% CI 98.2-100)
E25Bio, Rapid Diagnostic Test (LFA)							
[223] Pickering, f73.2	United Kingdom	AN/OP	banked	no	200	75.0% (95% CI 65.3*-83.1*)	86% (95% CI 77.6*-92.1*)
EcoDiagnostica, COVID-19 Ag (LFA)							
[180] Filgueiras, f14.1	Brazil	NP	fresh	unclear	150	69.1% (95% CI 55.2*-80.9*)	98.8% (95% CI 93.5*-100)
Fujirebio, ESPLINE® SARS-CoV-2 (LFA)							
[290] Takeda, a50.1	Japan	NP	unclear	no	162	80.6%* (95% CI 68.6*-89.6*)	100%* (95% CI 96.4*-100*)
[186] FINDdx, f92.1	Germany	NP/OP	fresh	no	723	78.6% (95% CI 69.8*-85.8*)	100% (95% CI 99.4-100)

[230] Sberna, f83.1	Italy	saliva	unclear	unclear	136	8.1% (95% CI 2.7-17.8)	100% (95% CI 95.1-100)
Fujirebio, Lumipulse® G SARS-CoV-2 Ag (requires reader)							
[189] Gili, f57.2	Italy	NP	banked	no	226	100% (95% CI 96.0*-100*)	92.1% (95% CI 90.7*-93.4*)
[189] Gili, f57.1	Italy	NP	fresh	no	1738	90.5% (95% CI 82.8*-95.6*)	91.6% (95% CI 85.5*-95.7*)
[193] Hirotsu, f47.1	Japan	NP	banked	no	1033	92.5% (95% CI 79.6*-98.4*)	100%* (95% CI 99.6*-100*)
[168] Basso, f10.1	Italy	NP	fresh	yes	234	81.6% (95% CI 71.9*-89.1*)	93.9%* (95% CI 88.7*-97.2*)
[166] Asai, f74.1	Japan	saliva	unclear	yes	305	77.8% (95% CI 65.5*-87.3*)	98.3% (95% CI 95.8*-99.5*)
[168] Basso, f10.2	Italy	saliva	fresh	yes	223	41.3% (95% CI 30.4-52.8)	98.6% (95% CI 95.0-99.8)
Guangzhou Wondfo Biotech, 2019-nCoV Antigen Test (LFA)							
[183] FINDdx, f41.1	Switzerland	NP	fresh	yes	328	85.7% (95% CI 73.8*-93.6*)	100% (95% CI 98.7*-100*)
Humasis, COVID-19 Ag Test (LFA)							
[169] Bruzzone, f86.2	Italy	unclear	banked	no	21	85.7% (95% CI 63.7*-97*)	not provided
Healgen, Rapid COVID-19 Ag Test (LFA)							
[178] Favresse, f31.3	Belgium	NP	fresh	no	188	77.1% (95% CI 67.4-85.1)	96.7% (95% CI 90.8-99.3)
ichroma, COVID-19 AG (requires reader)							
[181] FINDdx, f39.1	Switzerland	NP	fresh	yes	232	73.2% (95% CI 57.1*-85.8*)	100% (95% CI 98.0-100)
Innova Medical Group, INNOVA SARS-CoV-2 Antigen Rapid Qualitative Test (LFA)							
[223] Pickering, f73.1	United Kingdom	AN/OP	banked	no	200	89.0% (95% CI 81.2*-94.4*)	99.0% (95% CI 94.6-100)
[195] Houston, f25.1	United Kingdom	NP	fresh	yes	242	86.4% (95% CI 81.9*-90.2*)	95.1% (95% CI 92.7*-96.9*)
[223] Pickering, f73.10	United Kingdom	AN/OP	banked	no	23	82.6% (95% CI 61.2*-95.0*)	not provided
[223] Pickering, f73.11	United Kingdom	AN/OP	banked	no	23	82.6% (95% CI 61.2*-95.0*)	not provided
[222] Peto, f21.1	United Kingdom	unclear	unclear	unclear	6954	not provided	99.7% (95% CI 99.5*-99.8*)
[222] Peto, f21.4	United Kingdom	unclear	unclear	unclear	198	78.8% (95% CI 72.4-84.3)	not provided
[223] Pickering, f73.12	United Kingdom	AN/OP	banked	no	23	78.3% (95% CI 56.3*-92.5*)	not provided
[223] Pickering, f73.8	United Kingdom	AN/OP	banked	no	110	78.2% (95% CI 69.3*-85.5*)	not provided
[222] Peto, f21.3	United Kingdom	unclear	unclear	unclear	223	70.0% (95% CI 63.5-75.9)	not provided
[246] Young, f56.1	United Kingdom	NP	fresh	unclear	803	62.1%*(95% CI 55.3*-68.7*)	100% (95% CI 99.4-100)
[222] Peto, f21.2	United Kingdom	unclear	unclear	unclear	372	57.5% (95% CI 52.3-62.6)	not provided
[179] Ferguson, f85.1	United Kingdom	AN	fresh	yes	720	3.2% (95% CI 0.6-15.6)	100% (95% CI 99.5-100)
JOYSBIO Biotechnology, COVID-19 Antigen Rapid Test Kit (LFA)							
[182] FINDdx, f40.1	Switzerland	NP	fresh	yes	265	70.5% (95% CI 54.8*-83.2*)	99.1% (95% CI 96.8*-99.9*)
[194] Homza, f87.2	Czech Republic	NP	fresh	yes	225	57.8% (95% CI 46.9-68.1)	98.5% (95% CI 94.8-99.8)
Lab Care Diagnostics, PathoCatch/ACCUCARE SARS-CoV-2 Antigen Test (LFA)							
[239] Thakur, f88.1	India	NP	fresh	yes	677	34.5% (95% CI 24.5-45.6)	99.8% (95% CI 99.1-100)

Lepu Medical, SARS-CoV-2 Antigen Rapid Test Kit (LFA)							
[167] Baro, f33.4	Spain	NP	banked	no	286	45.5% (95% CI 35.6-55.8)	89.2% (95% CI 83.8-93.3)
Liming Bio, SARS-CoV-2 Ag-RDT (LFA)							
[295] Weitzel, a41.2	Chile	NP/OP	banked	no	19	0% (95% CI 0-29.9)	90.0% (95% CI 59.6-98.2)
LumiraDx, COVID-19 SARS-CoV-2 Antigen Test (requires reader)							
[176] Drain, f43.1	UK/US	AN	fresh	yes	257	97.6% (95% CI 91.6*-99.7*)	96.6% (95% CI 92.6*-98.7*)
[176] Drain, f43.2	UK/US	NP	fresh	yes	255	97.5% (95% CI 86.8*-99.9*)	97.7% (95% CI 94.7-99.2*)
[204] Krüger, f58.1	Germany	MT	fresh	yes	761	82.2% (95% CI 75.0*-88.0*)	99.3% (95% CI 98.3-99.7)
[169] Bruzzone, f86.6	Italy	unclear	banked	no	23	69.6% (95% CI 47.1*-86.8*)	not provided
[203] Kohmer, f32.4	Germany	NP	fresh	no	100	50.0% (95% CI 38.1-61.9)	100% (95% CI 86.8-100)
[211] Micocci, f77.1	United Kingdom	NP	fresh	unclear	241	75.0%* (95% CI 34.9*-96.8*)	96.1%* (95% CI 92.7*-98.2*)
MEDsan®, SARS-CoV-2 Antigen Rapid Test (LFA)							
[279] Olearo, a54.3	Germany	OP	unclear	no	184	45.2%* (95% CI 34.3*-56.5)	97.0% (95% CI 91.5-99.4*)
[244] Wagenhäuser, f89.3	Germany	OP	fresh	yes	3221	36.5% (95% CI 24.7*-49.6*)	99.6% (95% CI 99.3-99.8)
MOLOGIC, COVID-19 Rapid Antigen Test (LFA)							
[187] FINDdx, f93.1	Germany	AN/NMT	fresh	yes	665	90.7% (95% CI 85.7*-94.4*)	100% (95% CI 99.2-100)
NAL von minden, NADAL (LFA)							
[188] FINDdx, f94.1	Switzerland	NP	fresh	yes	462	88.4% (95% CI 78.4*-94.9*)	99.2% (95% CI 97.8-99.7)
[236] Strömer, f11.1	Germany	NP	banked	no	124	63.7%* (95% CI 54.6*-72.2*)	not provided
[244] Wagenhäuser, f89.1	Germany	OP	fresh	yes	806	56.5% (95% CI 34.5*-76.8*)	100% (95% CI 99.5-100)
[203] Kohmer, f32.3	Germany	NP	fresh	no	100	24.3% (95% CI 15.1-35.7)	100% (95% CI 86.8-100)
NanoEntek, FREND™ COVID-19 Ag (requires reader)							
[169] Bruzzone, f86.7	Italy	unclear	banked	no	60	93.3% (95% CI 83.8*-98.2*)	not provided
NDFOS, ND COVID-19 Ag Test (LFA)							
[194] Homza, f87.3	Czech Republic	NP	fresh	yes	191	70.1% (95% CI 58.6-80.0)	56.1% (95% CI 46.4-65.4)
Ortho Clinical Diagnostics, VITROS® SARS-CoV-2 Antigen Test (requires reader)							
[178] Favresse, f31.5	Belgium	NP	fresh	no	188	83.3% (95% CI 74.4-90.2)	100% (95% CI 96.1-100)
Precision Biosensors, Exdia COVID-19 Ag (requires reader)							
[170] Caruana, f34.3	Switzerland	NP	fresh	no	532	48.3% (95% CI 38.8*-57.8*)	99.5% (95% CI 98.3*-99.9*)
PRIMA, COVID-19 Antigen Rapid Test (LFA)							
[169] Bruzzone, f86.3	Italy	unclear	banked	no	50	66.0% (95% CI 51.2*-78.8*)	not provided
QUIDEL, Sofia SARS Antigen FIA (requires reader)							
[284] Porte, a32.1	Chile	NP/OP	banked	no	64	93.8% (95% CI 79.2*-99.2*)	96.9% (95% CI 83.8*-99.9*)
[196] Jääskeläinen, f50.1	Finland	NP	banked	no	188	80.4% (95% CI 73.1*-86.5*)	100% (95% CI 91.2*-100*)
[251] Beck, a04.1	USA	NP	fresh	yes	346	77.0% (95% CI 64.5*-86.8*)	99.6% (95% CI 98.1*-100*)
[265] Herrera, a46.1	USA	unclear	unclear	unclear	1172	76.8% (95% CI	99.2% (95% CI

						72.6-80.5)	98.2-99.7)
[190] Marti, f46.1	USA	MT	fresh	unclear	427	72.0% (95% CI 56.3*-84.7*)	99.7%* (95% CI 98.6*-100*)
RapiGEN, Biocredit Covid-19 Antigen Detection Kit (LFA)							
[289] Shrestha, a36.1	Nepal	NP	fresh	yes	113	85.0% (95% CI 71.7*-93.8*)	100% (95% CI 94.6*-100*)
[260] FINDdx, a62.1	Brazil	NP	fresh	yes	476	74.4% (95% CI 65.5*-82.0*)	98.9%* (95% CI 97.2-99.7*)
[295] Weitzel, a41.1	Chile	NP/OP	banked	no	109	62.0% (95% CI 50.4*-72.7*)	100% (95% CI 88.4*-100)
[233] Shidlovskaya, f61.1	Russia	NP	fresh	yes	106	56.4% (95% CI 44.7-67.6)	100% (95% CI 87.7-100)
[260] FINDdx, a62.2	Germany	ONP	fresh	yes	1239	52.0% (95% CI 31.3*-72.2*)	100% (95% CI 99.7-100)
[169] Bruzzone, f86.4	Italy	unclear	banked	no	23	39.1% (95% CI 19.7*-61.5*)	not provided
[286] Schildgen, a33.1	Germany	BAL/TW	unclear	no	73	33.3% (95% CI 19.6*-49.6*)	87.1% (95% CI 70.2*-96.4*)
[200] Kenyeres, f84.1	Hungary	NP	fresh	no	37	8.1% (95% CI 1.7*-21.9*)	not provided
R-Biopharm, RIDA®QUICK SARS-CoV-2 Antigen (LFA)							
[291] Toptan, a55.1	Germany	NP/OP	banked	no	67	77.6% (95% CI 64.7*-87.5*)	100% (95% CI 66.4*-100*)
[291] Toptan, a55.2	Germany	unclear	banked	no	70	50.0% (95% CI 31.9*-68.1*)	100% (95% CI 90.8*-100*)
[203] Kohmer, f32.1	Germany	NP	fresh	no	100	39.2% (95% CI 28.0-51.2)	96.2% (95% CI 80.4-99.9)
Roche, Elecsys® SARS-CoV-2 Antigen Test (requires reader)							
[216] Nörz, f78.1	Germany	NP/OP	banked	no	3139	60.2% (95% CI 55.2-65.1)	99.9% (95% CI 99.6-100)
Roche, SARS-CoV-2 Rapid Antigen Test (LFA)							
[240] Thell, f81.1	Austria	unclear	fresh	unclear	591	80.3% (95% CI 74.3-85.4)	99.1% (95% CI 97.4-99.8)
SD Biosensor, Standard F (requires reader)							
[284] Porte, a32.2	Chile	NP/OP	banked	no	64	90.6% (95% CI 75.0*-98.0*)	96.9% (95% CI 83.8*-99.9*)
[169] Bruzzone, f86.5	Italy	unclear	banked	no	60	86.7% (95% CI 75.4*-94.1*)	not provided
[261] FINDdx, a63.1	Brazil	NP	fresh	yes	453	77.5% (95% CI 69.0*-84.6*)	97.9% (95% CI 95.7-99.2*)
[261] FINDdx, a63.2	Germany	ONP	fresh	yes	676	69.2% (95% CI 52.4*-83.0*)	96.9% (95% CI 95.2-98.0)
[257] Drevinek, a10.2	Czech Republic	NP	fresh	yes	591	62.3% (95% CI 55.6*-68.7*)	99.5% (95% CI 98.0-99.9)
[219] Osterman, f20.1	Germany	NP/OP	unclear	no	360	60.9% (95% CI 53.5*-67.8*)	97.8% (95% CI 95.7-99.0*)
[273] Liotti, a22.1	Italy	NP	banked	no	359	47.1% (95% CI 37.1-57.1)	98.4% (95% CI 96.0-99.6)
SD Biosensor / Roche, Standard Q (LFA)							
[255] Chaimayo, a57.1	Thailand	NP/OP	banked	no	454	98.3% (95% CI 91.1-100)	98.7% (95% CI 97.1-99.6)
[169] Bruzzone, f86.1	Italy	unclear	banked	no	16	93.8% (95% CI 71.7-98.9)	not provided
[201] Kerneis, f69.1	France	NP	fresh	unclear	1109	94.2%* (95% CI 87.0*-98.1*)	99.0% (95% CI 98.2*-99.5*)
[287] Schwob, a35.1	Switzerland	NP	fresh	yes	333	92.9% (95% CI 86.4-96.9)	100% (95% CI 98.3*-100*)
[215] Nikolai, f35.3	Germany	NP	fresh	yes	96	91.2% (95% CI 76.3*-98.1*)	100% (95% CI 94.2-100)
[252] Berger, a05.2	Switzerland	NP	fresh	yes	529	89.0% (95% CI 83.7-93.1)	99.7% (95% CI 98.4-100)

[262] FINDdx, a64.1	Brazil	NP	fresh	yes	400	88.7% (95% CI 81.1*-94.0*)	97.6% (95% CI 95.2-99.0*)
[286] Schildgen, a33.3	Germany	BAL/TW	unclear	no	73	88.1% (95% CI 74.4*-96.0*)	19.4% (95% CI 7.5*-37.5*)
[207] Lindner, f15.1	Germany	NP	fresh	yes	139	85.0% (95% CI 70.2*-94.3*)	99.1% (95% CI 94.9*-100*)
[266] Igl□i, a15.1	Netherlands	NP	fresh	yes	970	84.9% (95% CI 79.0*-89.8*)	99.5% (95% CI 98.7-99.9*)
[264] Gupta, a13.1	India	NP	fresh	yes	330	81.8% (95% CI 71.4*-89.7*)	99.6% (95% CI 97.8-99.9)
[196] Jääskeläinen, f50.2	Finland	NP	banked	no	198	81.0% (95% CI 74.0*-86.8*)	100% (95% CI 91.2*-100*)
[242] Turcato, f09.1	Italy	NP	fresh	unclear	3410	80.3% (95% CI 74.4*-85.3*)	99.1% (95% CI 98.7*-99.4*)
[272] Lindner, a21.2	Germany	NP	fresh	yes	289	79.5% (95% CI 63.5*-90.7*)	99.6% (95% CI 97.8-100)
[245] Yin, f82.4	Belgium	NP	fresh	yes	65	78.3% (95% CI 58.1-90.3)	not provided
[4] Krüger, a17.1	Germany/England	NP/OP	unclear	no	1263	76.6% (95% CI 62.0*-87.7*)	99.3% (95% CI 98.6-99.7*)
[212] Möckel, f19.1	Germany	NP/OP	fresh	yes	271	75.3% (95% CI 65.0*-83.8*)	100% (95% CI 98.0*-100)
[272] Lindner, a21.1	Germany	AN/MT	fresh	no	289	74.4% (95% CI 57.9*87.0*)	99.2% (95% CI 97.1-99.9*)
[271] Lindner, a53.1	Germany	NP	fresh	yes	180	73.2%* (95% CI 57.1*-85.8*)	99.3% (95% CI 96.0-100)
[229] Salvagno, f54.1	Italy	NP	unclear	no	321	72.5% (95% CI 64.6-79.5)	99.4% (95% CI 96.8-100)
[254] Cerutti, a08.1	Italy	NP	unclear	no	185	72.1% (95% CI 62.5*-80.5*)	100% (95% CI 95.6*-100*)
[212] Möckel, f19.2	Germany	NP/OP	fresh	yes	2020	72.0% (95% CI 50.6*-87.9*)	99.4% (95% CI 96.9*-100*)
[268] Krüttgen, a16.1	Germany	NP	banked	no	150	70.7% (95% CI 59.0*-80.6*)	96.0% (95% CI 88.8*-99.2*)
[278] Nalumansi, a27.1	Uganda	NP	fresh	yes	262	70.0% (95% CI 59.4*-79.2*)	92.4%* (95% CI 87.4*-95.9*)
[220] Pena, f36.1	Chile	NP	fresh	yes	842	69.9% (95% CI 58.0*-80.1*)	99.6% (95% CI 98.9-99.9)
[178] Favresse, f31.4	Belgium	NP	fresh	no	188	69.8% (95% CI 59.6-78.8)	100% (95% CI 96.1-100)
[219] Osterman, f20.2	Germany	NP/OP	unclear	no	386	64.5% (95% CI 58.3*-70.3*)	97.7% (95% CI 95.6-98.9*)
[194] Homza, f87.4	Czech Republic	NP	fresh	yes	139	61.9% (95% CI 45.6-76.4)	99.0% (95% CI 94.4-100)
[231] Schuit, f64.2	Netherlands	NP	fresh	yes	1596	62.9% (95% CI 54.0-71.1)	99.5% (95% CI 98.9-99.8)
[226] Ristic, f44.1	Serbia	NP	fresh	unclear	120	58.1% (95% CI 42.1-73.0)	100% (95% CI 95.3*-100*)
[199] Kannian, f26.1	India	saliva	unclear	no	37	55.6%* (95% CI 35.3*-74.5*)	100% (95% CI 69.2*-100*)
[279] Olearo, a54.1	Germany	OP	unclear	no	184	48.8%* (95% CI 37.7*-60.0*)	100% (95% CI 96.4*-100)
[167] Baro, f33.3	Spain	NP	banked	no	286	43.6% (95% CI 33.7-53.8)	96.2% (95% CI 92.4-98.5)
[203] Kohmer, f32.2	Germany	NP	fresh	no	100	43.2% (95% CI 31.8*-55.3)	100% (95% CI 86.8-100)
[170] Caruana, f34.1	Switzerland	NP	fresh	no	532	41.2% (95% CI 32.1*-50.8*)	99.8%* (95% CI 98.7*-100*)
[254] Cerutti, a08.2	Italy	NP	fresh	no	145	40.0% (95% CI 5.3*-85.3*)	100% (95% CI 97.4*-100*)
[171] Caruana, f75.1	Switzerland	NP	fresh	unclear	116	28.6% (95% CI 3.7*-71.0*)	98.2% (95% CI 93.5*-99.8*)
SD Biosensor / Roche, Standard Q (nasal sampling) (LFA)							

[215] Nikolai, f35.4	Germany	MT	fresh	yes	96	91.2% (95% CI 76.3*-98.1*)	98.4% (95% CI 91.3*-100*)
[215] Nikolai, f35.2	Germany	MT	fresh	yes	132	86.1% (95% CI 70.5*-95.3*)	100% (95% CI 96.2*-100*)
[215] Nikolai, f35.1	Germany	AN	fresh	yes	132	86.1% (95% CI 70.5*-95.3*)	100% (95% CI 96.2*-100*)
[207] Lindner, f15.2	Germany	MT	fresh	yes	180	82.5% (95% CI 67.2*92.7*)	100% (95% CI 96.5-100)
[234] Stohr, f45.2	Netherlands	AN	fresh	unclear	1611	61.5% (95% CI 54.2*-68.4*)	99.7% (95% CI 99.3-99.9)
[271] Lindner, a53.2	Germany	AN	fresh	yes	179	80.5% (95% CI 65.1*-91.2*)	98.6% (95% CI 94.9-99.8*)
Shenzhen Lvshiyuan Biotechnology, Green Spring® SARS-CoV-2-Antigen-Schnelltest-Set (LFA)							
[223] Pickering, f73.4	United Kingdom	AN/OP	banked	no	200	77.0% (95% CI 67.5*-84.8*)	98.0% (95% CI 93.0-99.8*)
Shenzen Bioeasy Biotechnology, 2019-nCov Antigen Rapid Test Kit (requires reader)							
[285] Porte, a31.1	Chile	NP/OP	banked	no	127	93.9% (95% CI 86.3*-98.0*)	100% (95% CI 92.1*-100*)
[295] Weitzel, a41.4	Chile	NP/OP	banked	no	111	85.0% (95% CI 75.3*-92.0*)	100% (95% CI 88.8*-100)
[282] Parada-Ricart, a58.1	Spain	NP	fresh	yes	172	73.1%* (95% CI 52.2*-88.4*)	85.6%* (95% CI 78.9*-90.9*)
[4] Krüger, a17.2	Germany	NP/OP	fresh	no	727*	66.7% (95% CI 41.7-84.8)	93.1% (95% CI 91.0-94.8)
Siemens Healthineers, CLINITEST® Rapid COVID-19 Antigen Test (LFA)							
[241] Torres, f29.1	Spain	NP	fresh	yes	178	80.2% (95% CI 70.6*-87.8*)	100% (95% CI 95.8-100)
[241] Torres, f29.2	Spain	NP	fresh	yes	92	60.0% (95% CI 38.7*-78.9*)	100% (95% CI 94.6-100)
[279] Olearo, a54.4	Germany	OP	unclear	no	170	54.8%* (95% CI 43.5*-65.7*)	100% (95% CI 95.8*-100)
[167] Baro, f33.2	Spain	NP	banked	no	286	51.5% (95% CI 41.3-61.6)	98.4% (95% CI 95.3-99.7*)
SIENNA, COVID-19 Antigen Rapid Test (LFA)							
[209] Bouassa, f67.1	France	NP	banked	no	100	90.0% (95% CI 82.4*-95.1*)	100% (95% CI 92.9*-100)
Sugentech, SGTi-flex COVID-19 Ag (LFA)							
[233] Shidlovskaya, f61.2	Russia	NP	fresh	yes	106	52.6% (95% CI 40.9-64.0)	96.4% (95% CI 81.7-99.9)
SureScreen, COVID-19 Rapid Antigen Visual Read (LFA)							
[223] Pickering, f73.14	United Kingdom	AN/OP	banked	no	23	74.0%* (95% CI 51.6*-89.8*)	not provided
[223] Pickering, f73.3	United Kingdom	AN/OP	banked	no	200	65.0% (95% CI 54.8*-74.3*)	100% (95% CI 96.4*-100*)
[223] Pickering, f73.15	United Kingdom	AN/OP	banked	no	23	65.2% (95% CI 42.7*-83.6*)	not provided
[223] Pickering, f73.13	United Kingdom	AN/OP	banked	no	23	61.0%* (95% CI 38.5*-80.3*)	not provided
[167] Baro, f33.5	Spain	NP	banked	no	286	28.8% (95% CI 20.2-38.6)	97.8% (95% CI 94.5-99.4)
SureScreen, COVID-19 Rapid Antigen Flourescent (requires reader)							
[223] Pickering, f73.6	United Kingdom	AN/OP	banked	no	200	69.0% (95% CI 59.0*-77.9*)	98.0% (95% CI 93-99.8*)
[223] Pickering, f73.7	United Kingdom	AN/OP	banked	no	141	60.3% (95% CI 51.7*-68.4*)	not provided
VivaCheck, VivaDiag™ SARS-CoV-2 Ag Rapid Test (LFA)							
[194] Homza, f87.5	Czech Republic	NP	fresh	yes	268	41.8% (95% CI 31.5-52.6)	96.0% (95% CI 92.0-98.4)
Zhuhai Encode Medical Engineering, SARS-CoV-2 Antigen Rapid Test (LFA)							
[223] Pickering,	United Kingdom	AN/OP	banked	no	200	74.0% (95% CI	100% (95% CI

f73.5						64.3*-82.3*)	96.4*-100)
[223] Pickering, f73.9	United Kingdom	AN/OP	banked	no	90	74.4% (95% CI 64.2*-83.1*)	not provided

Caption: * Values differ from those provided in the respective manuscript due to missing or contradictory data. A list including the original data can be found in the Supplement (S4).
Data sets from an underlined author have not undergone peer-review yet (time of data extraction, 28.12.2020).
In data sets with underlined sample sizes the samples were used in head-to-head studies, performing different Ag-RDTs on the same patient.
Naming convention column "author": number in brackets relates to the list of sources. Letters behind the author's last name differentiates the data set from other data sets by the same author.
IFU = instructions for use; NP = nasopharyngeal; OP = oropharyngeal; AN = anterior nasal; MT = mid turbine; LRT = lower respiratory tract; BAL/TW = bronchoalveolar lavage and throat wash; CI = confidence interval.

Table 2: Summary clinical accuracy data for major Ag-RDTs not included in the meta-analysis

Manufacturer, Ag-RDT	Number of data sets	Sensitivity range	Specifcity range	Comments
Bionote, NowCheck® (LFA)	3	55.6% to 89.9%	97.3% to 100%	- Two of the studies were IFU-conform, whereas IFU-conformity for the study reporting 55.6% sensitivity was unclear
Denka, Quick Navi (LFA)	2	72.5% to 86.7%	100%*	- Both studies were conducted on fresh samples, but for the one reporting 72.5% IFU-conformity was unclear
Fujirebio, ESPLINE® SARS-CoV-2 (LFA)	3	8.1% to 80.7%	100%*	- The data set reporting 8.1% sensitivity used saliva samples (not IFU-conform) and the majority of samples showed a Ct-value > 25
JOYSBIO Biotechnology, COVID-19 Antigen Rapid Test Kit (LFA)	2	57.8% to 70.5%	98.5% to 99.1%	- The datasets used NP and AN samples, respectively. Both were performed by IFU on symptomatic people or high-risk contacts
MEDsan®, SARS-CoV-2 Antigen Rapid Test (LFA)	2	36.5% to 45.2%	97% to 99.6%	- Both studies were conducted on OP samples, which is IFU-conforming for this test
R-Biopharm, RIDA®QUICK SARS-CoV-2 Antigen (lateral flow assay)	3	39.2% to 77.6%	96.2% to 100%	- Two data sets originate from the same study and no study was conducted as per IFU - The data set reporting 39.2% included only asymptomatic persons with Ct-values between 22.1 and 36.4
Shenzen Bioeasy Biotechnology, 2019-nCov Antigen Rapid Test Kit (requires reader)	4	66.7% to 93.9%	85.6% to 100%	- The data set reporting 85.6% specificity was conducted IFU-conforming - The data sets reporting highest sensitivity were drawn from just symptomatic patients, for the others symptomatic patients made up more than two thirds of the study population
SureScreen, COVID-19 Rapid Antigen Flourescent (requires reader)	2	60.3% to 69.0%	98%*	- Both datasets originate from the same study and were conducted not IFU-conforming on stored samples
Zhuhai Encode Medical Engineering, SARS-CoV-2 Antigen Rapid Test (LFA)	2	74.0% to 74.4%	100%*	- Both datasets originate from the same study, a retrospective head-to-head comparison - Stored AN/MT samples were assessed

Caption: * only one data set for specificity was provided
IFU = instructions for use; Ag-RDT = antigen rapid diagnostic test; NP = nasopharyngeal; OP = oropharyngeal; AN = anterior nasal; MT = mid-turbinate.

PRISMA 2020 flow diagram for new systematic reviews which included searches of databases, registers and other sources




QUADAS−2 Domain
Flow and timing
Reference standard
Index test
Patient selection
0
25
50
75
100
High
Intermediate
Low
Unclear


QUADAS−2 Domain
Reference standard
Index test
Patient selection
0
25
50
75
100
High
Intermediate
Low
Unclear

Test assessed	N datasets	Total Sample Size	Pooled Sensitivity (95% CI)	Pooled Specificity (95% CI)
BD Veritor	6	6661	63.5% (49.3–75.8)	99.5% (98.8–99.8)
BinaxNOW	4	8163	61.8% (48–74)	99.8% (99.5–99.9)
CLINITEST	4	740	62.3% (47.4–75.2)	98.9% (97.1–99.6)
Coris	5	729	40% (28.7–52.4)	98.5% (95.4–99.5)
Lumipulse G	5	3532	87.2% (78–92.9)	96.7% (88.6–99.1)
LumiraDx	4	1373	88.2% (59–97.5)	98.6% (96.2–99.5)
Panbio	35	24472	71.8% (65.4–77.5)	99.4% (99.1–99.7)
Rapigen	6	2116	62% (46.7–75.2)	98.5% (94–99.6)
Sofia	5	2197	77.4% (74.2–80.3)	99.1% (98.3–99.5)
Standard F	6	2692	68.1% (55.5–78.5)	97.7% (96.6–98.5)
Standard Q	33	16478	74.9% (69.3–79.7)	98.6% (97.8–99.2)
Standard Q nasal	6	2271	80.2% (70.3–87.4)	99% (97.7–99.6)



Test assessed	Sensitivity N datasets	Sensitivity Total Sample Size	Pooled Sensitivity (95% CI)	Specificity N datasets	Specificity Total Sample Size	Pooled Specificity (95% CI)
Innova	10	2686	76.1% (68.1–84.1)	4	8668	99.4% (98.7–100)
Nadal	4	1492	58.4% (29.2–87.6)			
SureScreen V	4	269	65.9% (58.4–73.3)			



Ct Values	N datasets	Total Sample Size	Pooled Sensitivity (95% CI)
<20	22	741	96.5% (92.6–98.4)
>=20	12	598	94.4% (79.2–98.7)
<25	47	3004	95.8% (92.3–97.8)
>=25	24	987	50.7% (35.6–65.8)
<30	37	2879	79.9% (70.3–86.9)
>=30	29	509	20.9% (12.5–32.8)



Testing procedure	N datasets	Total Sample Size	Pooled Sensitivity (95% CI)	Pooled Specificity (95% CI)
IFU	81	49643	76.3% (73.1–79.2)	99.1% (98.8–99.4)
non−IFU	75	31416	65.9% (60.6–70.8)	98.3% (97.7–98.8)
unclear	17	14288	67.1% (55.8–76.7)	99.4% (99.2–99.6)



Sample type	N datasets	Total Sample Size	Pooled Sensitivity (95% CI)	Pooled Specificity (95% CI)
AN/MT	32	25814	75.5% (70.4–79.9)	99.2% (98.7–99.5)
NP	122	59810	71.6% (68.1–74.9)	98.9% (98.5–99.1)
OP	7	5165	53.1% (40.9–65)	99.3% (98.2–99.7)
saliva	4	1088	37.9% (11.8–73.5)	99.2% (97.5–99.7)
unclear	5	3251	77.4% (71.8–82.2)	99.1% (97–99.7)

Symptoms	N datasets	Total Sample Size	Pooled Sensitivity (95% CI)	Pooled Specificity (95% CI)
Asymptomatic	25	15228	52.5% (43.7–61.1)	99.1% (98.3–99.5)
Symptomatic	38	17964	76.7% (70.6–81.9)	99% (98.5–99.4)
Symptoms <7 days	12	5538	83.8% (76.3–89.2)	99.3% (99–99.6)
Symptoms >=7 days	10	397	61.5% (52.2–70)	96.8% (93.5–98.5)



	N datasets	Total Sample Size	Pooled Sensitivity (95% CI)	Pooled Specificity (95% CI)
Age <18 years	7	3837	64.3% (54.7–72.9)	99.4% (98.9–99.7)
Age >=18 years	16	7326	74.8% (66.5–81.6)	98.7% (97.2–99.4)